0001812360
false
0001812360
2023-07-14
2023-07-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date Earliest
Event Reported): July 14, 2023
FOXO
TECHNOLOGIES INC.
(Exact name of registrant
as specified in its charter)
Delaware |
|
001-39783 |
|
85-1050265 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
729 N. Washington Ave., Suite 600
Minneapolis, MN |
|
55401 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(612) 562-9447
(Registrant’s telephone
number, including area code)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Class A Common Stock, par value $0.0001 |
|
FOXO |
|
NYSE American |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
From July 14, 2023 through July
20, 2023 (each such date, a “First Tranche Closing Date”), FOXO Technologies Inc. (the
“Company”) entered into three separate Stock Purchase Agreements (the “Stock Purchase Agreements”),
which have substantially similar terms, with three accredited investors (the “Buyers”), pursuant to which the Company agreed
to issue and sell to the Buyers, in a private placement (the “Offering”), in two separate tranches each, an aggregate of up
to 5,625,000 shares of the Company’s Class A common stock, par value $0.0001 per share (“Common Stock”), at a price
of $0.08 per share (the “Per Share Price”), for aggregate gross proceeds of $450,000.
Pursuant to the terms of the Stock
Purchase Agreements, the Buyers initially purchased an aggregate of 2,812,500 shares of Common Stock (the “First Tranche Shares”)
on the applicable First Tranche Closing Dates, and agreed to purchase an aggregate of 2,812,500 additional shares of Common Stock (the “Second
Tranche Shares,” and collectively with the First Tranche Shares, the “Shares”) upon the effectiveness of the Resale
Registration Statement (as defined below).
Concurrently with the execution
of each Stock Purchase Agreement, the Company and the applicable Buyer entered into a Registration Rights Agreement (each, a “Registration
Rights Agreement”), dated as of the applicable First Tranche Closing Date, pursuant to which the Company is required, among other
things, to (i) file a resale registration statement (the “Resale Registration Statement”) with the U.S. Securities and Exchange
Commission (the “SEC”) covering the Shares within seven (7) calendar days following the execution of the applicable Registration
Rights Agreement (the “Filing Deadline”) and (ii) use its commercially reasonable efforts to have the Resale Registration
Statement declared effective by the SEC no later than forty-five (45) calendar days following the Filing Deadline (or, in the event of
a substantive review by the SEC, ninety (90) calendar days following the Filing Deadline) (the “Effectiveness Deadline”);
provided, however, if the SEC notifies the Company that the Resale Registration Statement will not be reviewed or is no longer subject
to further review and comments, then the Effectiveness Deadline will be the fifth (5th) trading day following the date on which the Company
is so notified (so long as the date of such fifth (5th) trading day precedes the dates otherwise required).
Pursuant to the Stock Purchase
Agreements, if, during the period from the applicable First Tranche Closing Date until ten (10) days after the effective date of the Resale
Registration Statement, the Company issues or sells any shares of Common Stock at a price per share less than the Per Share Price (a “Share
Dilutive Issuance”), except for Exempt Issuances (as defined in the Stock Purchase Agreements), then the Company will have to pay
to such Buyer, within two (2) business days after such Share Dilutive Issuance, a cash penalty in an amount equal to the number of Shares
theretofore purchased by such Buyer under the applicable Stock Purchase Agreement multiplied by the difference between (i) the Per Share
Price and (ii) the greater of (A) the price per share of Common Stock paid in the Share Dilutive Issuance and (B) $0.02 (the “Floor
Price”).
Additionally, pursuant to
the Stock Purchase Agreements, the Company is not permitted, from the date of the applicable Stock Purchase Agreement until ten (10) days
after the effective date of the Resale Registration Statement, to issue or sell, enter into any agreement to issue or sell, or announce
the issuance or sale or proposed issuance or sale of any Common Stock Equivalents (as defined in the Stock Purchase Agreements) or issue
or sell, enter into any agreement to issue or sell, or announce the issuance or sale or proposed issuance or sale of shares of Common
Stock, pursuant to which shares of Common Stock may be acquired at a per share price less than the Floor Price, except for (a) Exempt
Issuances or (b) the filing of a registration statement so long as such registration statement is not declared effective by the SEC during
the period from the date of the applicable Stock Purchase Agreement until ten (10) days after the effective date of the Resale Registration
Statement.
The Stock Purchase Agreements
and the Registration Rights Agreements contain customary representations, warranties, conditions and indemnification obligations of the
parties, which were made only for purposes of such Stock Purchase Agreements and Registration Rights Agreements as of specific dates and
solely for the benefit of the parties, and which may be subject to limitations agreed upon by the parties.
The Shares issued and to be
issued pursuant to the Stock Purchase Agreements were, and will be, sold pursuant to an exemption from the registration requirements under
Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated
thereunder. Each Buyer is an “accredited investor” as that term is defined in Rule 501(a)(1) under the Securities Act, and
has purchased, and will purchase, the Shares as an investment in the Offering, which did not involve a general solicitation. The Shares
have not been registered under the Securities Act and may not be offered or sold in the United States in the absence of an effective registration
statement or exemption from the registration requirements of the Securities Act. This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer,
solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.
Joseph
Gunnar & Co., LLC acted as the Company’s sole placement agent (the “Placement Agent”) on a “commercially
reasonable efforts” and exclusive basis in connection with the Offering, pursuant to the terms of that certain Engagement Letter,
dated as of January 5, 2023, by and between the Company and the Placement Agent. The Placement Agent’s compensation under the Engagement
Letter includes: (i) a cash fee, payable upon each closing of the Offering, equal to ten percent (10.0%) of the gross proceeds received
by the Company in the Offering and (ii) the reimbursement of up to a total of $75,000 for certain incurred expenses and legal fees.
The foregoing summaries of
the Stock Purchase Agreements and the Registration Rights Agreements do not purport to be complete descriptions and are qualified in their
entirety by reference to the full text of the forms of Stock Purchase Agreement and Registration Rights Agreement, which are attached
hereto as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
To the extent required by this
Item 3.02, the information set forth in Item 1.01 above is incorporated herein by reference.
As of July 20, 2023, after taking
into account the issuance of the First Tranche Shares, the Company has 49,293,392 shares of Common Stock issued and outstanding.
Item 8.01 Other Events.
Together with other cost saving
measures that the Company expects to implement in the near-term, the Company expects the additional $202,500 in net proceeds from the
sale of the First Tranche Shares to be sufficient to fund its operations through the end of July 2023, and the Company expects the anticipated
$202,500 in net proceeds from the sale of the Second Tranche Shares to be sufficient to fund its operations through mid August 2023. The
amounts of net proceeds in the foregoing sentence do not give effect to the payment of legal fees and other expenses in connection with
the Offering. In the event that the Company is unable to secure financing by that time, it may be forced to further curtail or suspend
its operations, sell the Company, or possibly even file for bankruptcy or liquidate assets and wind-up and dissolve the Company.
In connection with the preparation
and review of its financial statements for the quarter ended June 30, 2023, the Company determined that such financial statements will
likely include an impairment charge related to its intangible assets. The Company currently estimates that such impairment charge will
be approximately $1.2 million in the aggregate, consisting of an impairment charge of approximately $630,000 for the Company’s underwriting
application programming interface (“API”) and an impairment charge of approximately $578,000 for the Company’s longevity
API. The Company does not expect the impairment charges to result in any cash expenditures. These amounts reflect the Company’s
best estimates of the impairment charges at this time; however, such amounts continue to be evaluated and the Company can make no assurances
that these estimates will not change. The Company notes that the impairment charge would have occurred irrespective of the Offering and
would have been, and will be, reflected in its financial statements for the quarter ended June 30, 2023.
Cautionary Note Regarding Forward-Looking Statements
The information contained in this
Current Report on Form 8-K and the exhibits attached hereto contain “forward-looking” statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The words “intend,” “may,” “should,” “would,”
“expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other comparable terminology are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are
statements that are not historical facts. Such forward-looking statements are not guarantees of future performance and are subject to
risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due
to many factors. With respect to the matters addressed in this Current Report on Form 8-K, those factors include, but are not limited
to: whether the Resale Registration Statement will be declared effective by the SEC promptly, if at all, the Company’s ability to
timely obtain the net proceeds from the sale of the Second Tranche Shares as well as additional funding to continue its operations, the
Company’s ability to implement cost savings measures and to realize the anticipated benefits and the estimates of the impairment
charges that the Company may incur. While the Company believes its plans, intentions and expectations reflected in those forward-looking
statements are reasonable, these plans, intentions or expectations may not be achieved. The Company’s actual results, performance
or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements. For information
about the factors that could cause such differences, please refer to the Company’s filings with the SEC. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. The Company assumes no obligation to update any forward-looking
statement.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
FOXO Technologies Inc. |
|
|
|
Date: July 20, 2023 |
By: |
/s/ Tyler Danielson |
|
|
Name: |
Tyler Danielson |
|
|
Title: |
Interim Chief Executive Officer |
|
|
|
|
Exhibit 10.1
Stock Purchase
Agreement
By and Between
FOXO Technologies
Inc.
and
[●]
July [●],
2023
Stock
Purchase Agreement
THIS STOCK PURCHASE AGREEMENT
(together with all exhibits and schedules hereto, this “Agreement”) is entered into as of July [●], 2023, by and between
FOXO Technologies Inc., a Delaware corporation (the “Company”), and [●] (the “Buyer”),
with an address at [●]. The Company and Buyer may be collectively referred to herein as the “Parties” and individually
as a “Party.”
WHEREAS, this Agreement is
one of a series of substantially similar Stock Purchase Agreements that the Company has entered into or may in the future enter into,
with other investors, in connection with the private placement of the Company’s Class A common stock, $0.0001 par value (“Common
Stock”);
WHEREAS, the Company desires
to sell to Buyer, and Buyer wishes to purchase from the Company, an aggregate of [●] shares of Common Stock, subject to adjustment
as set forth in this Agreement (collectively, the “Shares”), in two (2) separate tranches as set forth in Article II herein,
subject to the terms and conditions set forth herein;
WHEREAS, the Company and
the Buyer are executing and delivering this Agreement in reliance upon the exemption from the registration requirements of the Securities
Act (as defined below) afforded by Section 4(a)(2) of the Securities Act (as defined below) and Rule 506 promulgated thereunder (without
limiting any other such exemption which may apply to the transactions contemplated by this Agreement) and in reliance upon specific exemptions
from the registration or qualification requirements of applicable state securities laws; and
WHEREAS, concurrently with
the execution and delivery of this Agreement at the First Tranche Closing, the Parties hereto shall execute and deliver at the First
Tranche Closing a Registration Rights Agreement, in the form attached hereto as Exhibit A (the “Registration Rights Agreement”),
pursuant to which the Company has agreed to provide certain registration rights with respect to the Shares under the Securities Act.
NOW, THEREFORE, in consideration
of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties agree as follows:
Article I. Definitions
Section 1.01 Definitions.
In addition to the terms defined elsewhere in this Agreement, the following terms, as used herein, have the following meanings:
| (a) | “Affiliate” means any Person that, directly or
indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are
used in and construed under Rule 405 under the Securities Act. |
| (b) | “Business Day” means any day other than Saturday,
Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however,
for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home,”
“shelter-in-place,” “non-essential employee” or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including
for wire transfers) of commercial banks in The City of New York are generally are open for use by customers on such day. |
| (c) | “Disclosure Schedules” means the Disclosure Schedules
of the Company delivered concurrently herewith. |
| (d) | “Governmental Entity” means any federal, state,
municipal, local, or foreign government and any court, tribunal, arbitral body, administrative agency, department, subdivision, entity,
commission or other governmental, government appointed, quasi-governmental or regulatory authority, reporting entity or agency, domestic,
foreign, or supranational. |
| (e) | “Knowledge of the Company” or “Knowledge”
when used in reference to the Company means the actual knowledge of Tyler Danielson, Michael Will, and Robby Potashnick. |
| (f) | “Law” means any applicable foreign, federal,
state, or local law (including common law), statute, treaty, rule, directive, regulation, ordinances and similar provisions having the
force or effect of law or an Order of any Governmental Entity. |
| (g) | “Liabilities” means liabilities, obligations,
or responsibilities of any nature whatsoever, whether direct or indirect, matured, or un-matured, fixed, or unfixed, known, or unknown,
asserted or unasserted, choate or inchoate, liquidated, or unliquidated, secured, or unsecured, absolute, contingent, or otherwise, including
any direct or indirect indebtedness, guaranty, endorsement, claim, loss, damage, deficiency, cost, or expense. |
| (h) | “Lien” means, with respect to any property or
asset, any lien, security interest, mortgage, pledge, charge, claim, right of first refusal, restrictive easement, charge or any other
restriction of any kind, and any conditional sale or voting agreement or proxy, and including any restriction on the ownership, use,
voting, transfer, possession, receipt of income or other exercise of any attributes of ownership, in respect of such property or asset,
and any agreement to give any of the foregoing. |
| (i) | “Losses” means any losses, damages, deficiencies,
Liabilities, assessments, fines, penalties, judgments, actions, claims, costs, disbursements, fees, expenses or settlements of any kind
or nature, including legal, accounting, and other professional fees and expenses. |
| (j) | “Material Adverse Effect” means (i) a material
adverse effect on the legality, validity or enforceability of this Agreement or the Registration Rights Agreement, (ii) a material adverse
effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken
as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its
obligations under this Agreement or the Registration Rights Agreement; provided, that none of the following, and no changes, effects,
events, circumstances, occurrences or states of facts arising out of or resulting from the following, shall be deemed, either alone or
in combination, to constitute a Material Adverse Effect, or be taken into account in determining whether there has been a Material Adverse
Effect, to the extent the following do not materially and disproportionately impact the Company, taken as a whole, compared to other
companies in the industry or industries in which the Company operates, in which case the extent of such material and disproportionate
effect may be taken into account in determining whether a Material Adverse Effect has occurred: (a) changes or effects in general economic
conditions, (b) changes in Laws or GAAP (or other analogous accounting standards) or the enforcement thereof, (c) changes or effects,
including legal, tax or regulatory changes, that generally affect the industry or industry sectors in which the Company operates, (d)
any changes or effects that arise out of or are attributable to the commencement, occurrence, continuation or intensification of any
war, sabotage, armed hostilities, acts of terrorism, labor dispute, strike, lockout, civil commotion, riot, act of God, fire, flood,
earthquake or other casualty, shortage of labor or materials, governmental law, regulation, or restriction, pandemic, epidemic, quarantine
order, or other action or event customarily defined as force majeure or (e) changes or effects that arise out of or are attributable
to the negotiation, execution, public announcement, pendency or performance of the Transaction Documents or the compliance with the provisions
thereof. |
| (k) | “Order” means any judgment,
writ, decree, determination, award, compliance agreement, settlement agreement, injunction,
ruling, charge, judicial or administrative order, determination or other restriction of any
Governmental Entity or arbitrator. |
| (l) | “Person” means a natural
person, a corporation, a limited liability company, a partnership (general or limited), an
association, a trust or any other entity or organization, including a government or political
subdivision or any agency or instrumentality thereof. |
| (m) | “Principal Market” means
any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any successors
to any of the foregoing) or a principal quotation system (i.e., OTCQX, OTCQB, OTC Pink, the
OTC Bulletin Board). |
| (n) | “Registration Statement”
shall have the meaning assigned to such term in the Registration Rights Agreement. |
| (o) | “Securities Act” means the
United States Securities Act of 1933, as amended, and the rules and regulation promulgated
thereunder. |
| (p) | “Subsidiary” means any significant
subsidiary of the Company as defined in Article 1, Rule 1-02 of Regulation S-X promulgated
pursuant to the Securities Act. |
| (q) | “Transactions” means the
purchase and sale of the Shares and the other transactions contemplated under this Agreement
and the Registration Rights Agreement. |
| (r) | “Transaction Documents”
means this Agreement, the Registration Rights Agreement, all exhibits, and schedules thereto
and hereto and any other documents or agreements executed in connection with the transactions
contemplated hereunder. |
Section 1.02 Interpretive
Provisions. Unless the express context otherwise requires, the words “hereof,” “herein,” and
“hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not
to any particular provision of this Agreement; terms defined in the singular shall have a comparable meaning when used in the
plural, and vice versa; the terms “Dollars” and “$” mean United States Dollars, unless otherwise specified
herein; references herein to a specific Section, Subsection, Recital or Exhibit shall refer, respectively, to Sections,
Subsections, Recitals or Exhibits of this Agreement; wherever the word “include,” “includes,”
“included” or “including” is used in this Agreement, it shall be deemed to be followed by the words
“without limitation”; references herein to any gender shall include each other gender; references herein to any Person
shall include such Person’s heirs, executors, personal representatives, attorneys, administrators, successors and assigns; provided, however,
that nothing contained in this Section 1.02 is intended to authorize any assignment or transfer not otherwise permitted by this
Agreement; references herein to a Person in a particular capacity or capacities shall exclude such Person in any other capacity;
references herein to any, accord, contract or agreement (including this Agreement) mean such, accord, contract or agreement as
amended, supplemented or modified from time-to-time in accordance with the terms thereof; with respect to the determination of any
period of time, the word “from” means “from and including” and the words “to” and
“until” each means “to but excluding”; references herein to any Law or any license mean such Law or license
as amended, modified, codified, reenacted, supplemented or superseded in whole or in part, and in effect from time-to-time or
otherwise amended; and references herein to any Law shall be deemed also to refer to all rules and regulations promulgated
thereunder, which are applicable or could be deemed applicable.
Article II.
Purchase and Sale
Section 2.01 Purchase and
Sale.
| (a) | First Tranche Closing. In accordance with the terms
and subject to the satisfaction (or where legally permissible, the waiver) of the conditions set forth in Section 2.05 of this Agreement,
at the First Tranche Closing (as defined herein), the Company shall sell, issue, convey and irrevocably deliver to the Buyer, and the
Buyer shall purchase accept and acquire from the Company [●] shares of Common Stock, subject to adjustment as provided in this
Agreement (the “First Tranche Purchase Shares”), free and clear of all Liens, fully paid and non-assessable. |
| (b) | Second Tranche Closing. In accordance with the terms
and subject to the satisfaction (or where legally permissible, the waiver) of the conditions set forth in Section 2.06 of this Agreement,
at the Second Tranche Closing (as defined herein), the Company shall sell, issue, convey and irrevocably deliver to the Buyer, and the
Buyer shall purchase accept and acquire from the Company [●] shares of Common Stock, subject to adjustment as provided in this
Agreement (the “Second Tranche Purchase Shares”), free and clear of all Liens, fully paid and non-assessable. |
Section 2.02 Purchase
Price. The total purchase price for the First Tranche Purchase Shares shall be $[●] (the “First Tranche Purchase
Price”), for a per share purchase price of $0.08, subject to adjustment as provided in this Agreement (the “Per Share
Price”). The total purchase price for the Second Tranche Purchase Shares shall be $[●] (the “Second Tranche
Purchase Price”), for the Per Share Price in this Agreement.
Section 2.03 Issuance of
Shares Against Payment Therefor at Closing.
| (a) | First Tranche Closing. At the
First Tranche Closing, the Buyer shall deliver the First Tranche Purchase Price to the Company
via wire transfer or “Automated Clearing House” payment (“ACH”) to
an account as designated by the Company. At the First Tranche Closing, the Company shall
deliver irrevocable instructions to its transfer agent and take all such other actions necessary
to cause its transfer agent to issue and deliver to the Buyer, within two (2) Business Days
after the First Tranche Closing, a direct registration book entry statement (a “DRS
Statement”) reflecting the First Tranche Purchase Shares purchased by the Buyer at
the First Tranche Closing, which DRS Statement (and any subsequent DRS Statement or stock
certificate evidencing First Tranche Purchase Shares that may be issued subsequent to the
First Tranche Closing) shall, except as otherwise provided in Section 5.02 hereof, include
the restrictive legend set forth in Section 4.04(j) noting that the First Tranche Purchase
Shares are subject to restrictions on transfer thereof under the Securities Act, and a stop
transfer order shall be maintained against the transfer of such First Tranche Purchase Shares. |
| (b) | Second Tranche Closing. At the
Second Tranche Closing, the Buyer shall deliver the Second Tranche Purchase Price to the
Company via wire transfer or ACH payment to an account as designated by the Company. At the
Second Tranche Closing, in accordance with the instructions of the Buyer, the Company shall
deliver irrevocable instructions to its transfer agent and take all such other actions necessary
to cause its transfer agent to (i) issue and deliver to the Buyer, within two (2) Business
Days after the Second Tranche Closing, a DRS Statement reflecting the Second Tranche Purchase
Shares purchased by the Buyer at the Second Tranche Closing, which DRS Statement shall not
bear any restrictive or other legends and shall be freely tradable and transferable and without
restriction on transfer or (ii) credit the Buyer’s or its designee’s account
at DTC through its Deposit/Withdrawal at Custodian (DWAC) system, within two (2) Business
Days after the Second Tranche Closing, with a number of shares of Common Stock equal to the
number of Second Tranche Purchase Shares to be purchased by the Buyer at the Second Tranche
Closing, which shall not bear any restrictive or other legends and shall be freely tradable
and transferable and without restriction on transfer. The First Tranche Closing and the Second
Tranche Closing are each sometimes referred to in this Agreement as a “Closing”
and together sometimes referred to in this Agreement as the “Closings.” |
Section 2.04 Closings.
| (a) | First Tranche Closing. This Agreement
shall become effective and binding upon the execution and delivery of counterpart signature
pages of this Agreement and the Registration Rights Agreement executed by each of the Parties
hereto in accordance with Section 6.14 hereof on or prior to the First Tranche Closing Date.
The payment of the First Tranche Purchase Price for, against delivery of, the First Tranche
Purchase Shares as contemplated by Sections 2.01(a) and 2.03(a) hereof, together with the
delivery and exchange of all other documents, instruments and writings required to be delivered
by the Parties in connection therewith as provided in Section 2.05 hereof (the “First
Tranche Closing”), shall take place on the first (1st) Business Day (which
may be the date hereof) on which each of the conditions precedent to the First Tranche Closing
set forth in Section 2.05 below are satisfied (or where legally permissible, waived) (the
date on which the First Tranche Closing occurs, the “First Tranche Closing Date”). |
| (b) | Second Tranche Closing. The payment
of the Second Tranche Purchase Price for, against delivery of, the Second Tranche Purchase
Shares as contemplated by Sections 2.01(b) and 2.03(b) hereof, together with the delivery
and exchange of all other documents, instruments and writings required to be delivered by
the Parties in connection therewith as provided in Section 2.06 hereof (the “Second
Tranche Closing”), shall take place on the second (2nd) Business Day immediately
following the effective date of the Initial Registration Statement (as defined in the Registration
Rights Agreement) filed by the Company pursuant to the Registration Rights Agreement (the
date on which the Second Tranche Closing occurs, the “Second Tranche Closing Date”),
provided that each of the conditions precedent to the Second Tranche Closing set forth in
Section 2.06 below have been satisfied at or prior to the Second Tranche Closing as provided
in Section 2.06. The First Tranche Closing Date and the Second Tranche Closing Date are each
sometimes referred to in this Agreement as a “Closing Date.” |
Section 2.05 First Tranche
Closing Conditions.
(a) Conditions
of the Company to the First Tranche Closing. The obligation of the Company to sell and issue the First Tranche Purchase Shares to
the Buyer at the First Tranche Closing is subject to the fulfillment, to the Company’s reasonable satisfaction, or (where legally
permissible) the waiver by the Company, on or prior to the First Tranche Closing Date, of each of the following conditions:
(i) Representations
and Warranties. The representations and warranties of the Buyer contained in this Agreement (x) that are not qualified by “materiality”
shall have been true and correct in all material respects when made and shall be true and correct in all material respects as of the
First Tranche Closing Date with the same force and effect as if made on such dates, except to the extent such representations and warranties
are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such
other date and (y) that are qualified by “materiality” shall have been true and correct when made and shall be true
and correct as of the First Tranche Closing Date with the same force and effect as if made on such dates, except to the extent such representations
and warranties are as of another date, in which case, such representations and warranties shall be true and correct as of such other
date.
(ii) Buyer’s
Execution and Delivery of Agreements. On or prior to the First Tranche Closing Date, the Buyer shall have (A) duly executed and delivered
counterpart signature pages of this Agreement and the Registration Rights Agreement in accordance with Sections 2.04(a) and 6.14 hereof
and (B) delivered a completed Buyer Questionnaire in the form attached hereto as Exhibit B.
(iii) No
Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened,
or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of, or which would materially
modify or delay any of, the transactions contemplated by the Transaction Documents.
(b) Conditions
to the Buyer to the First Tranche Closing. The obligation of the Buyer to purchase the First Tranche Purchase Shares at the First
Tranche Closing is subject to the Buyer’s reasonable satisfaction, or (where legally permissible) the waiver by the Buyer, on or
prior to the First Tranche Closing Date, of each of the following conditions:
(i) Representations
and Warranties. The representations and warranties of the Company contained in this Agreement (x) that are not qualified by “materiality”
or “Material Adverse Effect” shall have been true and correct in all material respects when made and shall be true and correct
in all material respects as of the First Tranche Closing Date with the same force and effect as if made on such dates, except to the
extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and
correct in all material respects as of such other date and (y) that are qualified by “materiality” or “Material
Adverse Effect” shall have been true and correct when made and shall be true and correct as of the First Tranche Closing Date with
the same force and effect as if made on such dates, except to the extent such representations and warranties are as of another date,
in which case, such representations and warranties shall be true and correct as of such other date.
(ii) Performance
of the Company. The Company shall have performed, satisfied, and complied in all material respects with all covenants, agreements
and conditions required by this Agreement and the Registration Rights Agreement to be performed, satisfied, or complied with by the Company
on or prior to the First Tranche Closing Date.
(iii) Company’s
Execution and Delivery of Agreements. The Company shall have duly executed and delivered counterpart signature pages of this
Agreement and the Registration Rights Agreement in accordance with Sections 2.04(a) and 6.14 hereof on or prior to the First Tranche
Closing Date.
(iv) No
Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended by the
Commission, the Principal Market or the Financial Industry Regulatory Authority (“FINRA”) (except for any suspension of trading
of less than three (3) days, which suspension shall be terminated prior to the First Tranche Closing Date), the Company shall not have
received any final and non-appealable notice that the listing or quotation of the Common Stock on the Principal Market shall be terminated
on a date certain (unless, prior to such date certain, the Common Stock is listed or quoted on any other U.S. national securities exchange),
trading in securities generally as reported on the Principal Market shall not have been suspended or limited, nor shall a banking moratorium
have been declared either by the U.S. or New York State authorities (except for any suspension, limitation or moratorium which shall
be terminated prior to the First Tranche Closing Notice Date), there shall not have been imposed any suspension of electronic trading
or settlement services by the Depository Trust Company (“DTC”) with respect to the Common Stock that is continuing, and the
Company shall not have received any notice from DTC to the effect that a suspension of electronic trading or settlement services by DTC
with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension, DTC shall have notified the Company
in writing that DTC has determined not to impose any such suspension).
(v) Compliance
with Laws. The Company shall have complied with all applicable federal, state and local governmental laws, rules, regulations and
ordinances in connection with the execution, delivery and performance of this Agreement and the Registration Rights Agreement and the
consummation of the Transactions, including, without limitation, the Company shall have obtained all permits and qualifications required
by any applicable state securities or “Blue Sky” laws for the offer and sale of the Shares by the Company to the Buyer.
(vi) No
Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened
or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of, or which would materially
modify or delay any of, the Transactions.
(vii) No
Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority shall have
been commenced or threatened, and no inquiry or investigation by any governmental authority shall have been commenced or threatened,
against the Company, or any of the officers, directors, or affiliates of the Company, seeking to restrain, prevent or change the Transactions,
or seeking material damages in connection with the Transactions.
(viii) Listing
of First Tranche Purchase Shares. The Company shall have submitted a supplemental listing application to NYSE American with respect
to the issuance of the First Tranche Purchase Shares and Second Tranche Purchase Shares to be issued and sold to the Buyer at the First
Tranche Closing and Second Tranche Closing at or prior to the First Tranche Closing.
(ix) Delivery
of Irrevocable Transfer Agent Instructions. At the First Tranche Closing, the Company shall have delivered irrevocable instructions
to its transfer agent to issue and deliver to the Buyer, within two (2) Business Days after the First Tranche Closing, one or more DRS
Statements reflecting the First Tranche Purchase Shares purchased by the Buyer at the First Tranche Closing.
(x) No
Material Adverse Effect. No condition, occurrence, state of facts or event constituting a Material Adverse Effect shall have occurred
and be continuing.
(xi) Current
Public Information. All reports, schedules, registrations, forms, statements, information, and other documents required to have been
filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required
to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, shall have been filed with the Commission under the Exchange
Act.
Section 2.06 Second Tranche
Closing Conditions.
(a) Conditions
of the Company to the Second Tranche Closing. The obligation of the Company to sell and issue the Second Tranche Purchase Shares
to the Buyer at the Second Tranche Closing is subject to the fulfillment, to the Company’s reasonable satisfaction, or (where legally
permissible) the waiver by the Company, on or prior to the Second Tranche Closing Date, of each of the following conditions:
(i) Representations
and Warranties. The representations and warranties of the Buyer contained in this Agreement (x) that are not qualified by “materiality”
shall have been true and correct in all material respects when made and shall be true and correct in all material respects as of the
Second Tranche Closing Date with the same force and effect as if made on such dates, except to the extent such representations and warranties
are as of another date, in which case, such representations and warranties shall be true and correct in all material respects as of such
other date and (y) that are qualified by “materiality” shall have been true and correct when made and shall be true
and correct as of the Second Tranche Closing Date with the same force and effect as if made on such dates, except to the extent such
representations and warranties are as of another date, in which case, such representations and warranties shall be true and correct as
of such other date.
(ii) No
Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened,
or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of, or which would materially
modify or delay any of, the Transactions.
(b) Conditions
of the Buyer to the Second Tranche Closing. The obligation of the Buyer to purchase the Second Tranche Purchase Shares at the Second
Tranche Closing is subject to the Buyer’s reasonable satisfaction, on or prior to the Second Tranche Closing Date, of each of the
following conditions:
(i) Representations
and Warranties. The representations and warranties of the Company contained in this Agreement (x) that are not qualified by “materiality”
or “Material Adverse Effect” shall have been true and correct in all material respects when made and shall be true and correct
in all material respects as of the Second Tranche Closing Date with the same force and effect as if made on such dates, except to the
extent such representations and warranties are as of another date, in which case, such representations and warranties shall be true and
correct in all material respects as of such other date and (y) that are qualified by “materiality” or “Material
Adverse Effect” shall have been true and correct when made and shall be true and correct as of the Second Tranche Closing Date
with the same force and effect as if made on such dates, except to the extent such representations and warranties are as of another date,
in which case, such representations and warranties shall be true and correct as of such other date.
(ii) Performance
of the Company. The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements
and conditions required by this Agreement and the Registration Rights Agreement to be performed, satisfied, or complied with by the Company
on or prior to the Second Tranche Closing Date.
(iii) Registration
Statement Effective. The Initial Registration Statement (as defined in the Registration Rights Agreement) registering the resale
by the Buyer of all of the First Tranche Purchase Shares purchased by the Buyer at the First Tranche Closing and all of the Second Tranche
Purchase Shares to be purchased by the Buyer at the Second Tranche Closing pursuant to this Agreement shall have been declared effective
by the Commission under the Securities Act and shall remain effective as of the Second Tranche Closing Date.
(iv) No
Material Notices. None of the following events shall have occurred and be continuing: (a) receipt of any request by the Commission
or any other federal or state governmental authority for any additional information relating to the Registration Statement, the prospectus
included therein or any supplement to the prospectus, or for any amendment of or supplement to the Registration Statement, the prospectus
included therein, or any supplement to the prospectus; (b) the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of the Registration Statement or prohibiting or suspending the use of the prospectus
included therein or any supplement to the prospectus, or of the suspension of qualification or exemption from qualification of the Shares
for offering or sale in any jurisdiction, or the initiation or contemplated initiation of any proceeding for such purpose; or (c) the
occurrence of any event or the existence of any condition or state of facts, which makes any statement of a material fact made in the
Registration Statement, the Prospectus or any Prospectus Supplement untrue or which requires the making of any additions to or changes
to the statements then made in the Registration Statement, the prospectus included therein or any prospectus supplement thereto in order
to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein
(in the case of the prospectus or any prospectus supplement, in light of the circumstances under which they were made) not misleading,
or which requires an amendment to the Registration Statement or a supplement to the prospectus or any prospectus supplement to comply
with the Securities Act or any other law. The Company shall have no Knowledge of any event that could reasonably be expected to have
the effect of causing the suspension of the effectiveness of the Registration Statement or the prohibition or suspension of the use of
the prospectus included therein or any prospectus supplement thereto in connection with the resale of the Shares by the Buyer.
(v) No
Suspension of Trading in or Notice of Delisting of Common Stock. Trading in the Common Stock shall not have been suspended by the
Commission, the Principal Market or FINRA (except for any suspension of trading of less than three (3) days, which suspension shall be
terminated prior to the Second Tranche Closing Date), the Company shall not have received any final and non-appealable notice that the
listing or quotation of the Common Stock on the Principal Market shall be terminated on a date certain (unless, prior to such date certain,
the Common Stock is listed or quoted on any other U.S. national securities exchange), trading in securities generally as reported on
the Principal Market shall not have been suspended or limited, nor shall a banking moratorium have been declared either by the U.S. or
New York State authorities (except for any suspension, limitation or moratorium which shall be terminated prior to the Second Tranche
Closing Date), there shall not have been imposed any suspension of electronic trading or settlement services by DTC with respect to the
Common Stock that is continuing, and the Company shall not have received any notice from DTC to the effect that a suspension of electronic
trading or settlement services by DTC with respect to the Common Stock is being imposed or is contemplated (unless, prior to such suspension,
DTC shall have notified the Company in writing that DTC has determined not to impose any such suspension).
(vi) Compliance
with Laws. The Company shall have complied with all applicable federal, state and local governmental laws, rules, regulations and
ordinances in connection with the execution, delivery and performance of this Agreement and the Registration Rights Agreement and the
consummation of the Transactions, including, without limitation, the Company shall have obtained all permits and qualifications required
by any applicable state securities or “Blue Sky” laws for the offer and sale of the Shares by the Company to the Buyer and
the subsequent resale of the Shares by the Buyer (or shall have the availability of exemptions therefrom).
(vii) No
Injunction. No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened
or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of, or which would materially
modify or delay any of, the Transactions.
(viii) No
Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any court or governmental authority shall have
been commenced or threatened, and no inquiry or investigation by any governmental authority shall have been commenced or threatened,
against the Company, or any of the officers, directors or affiliates of the Company, seeking to restrain, prevent or change the transactions
contemplated by this Agreement and the Registration Rights Agreement, or seeking material damages in connection with the Transactions.
(ix) Listing
of Second Tranche Purchase Shares. The Principal Market shall not have objected to the issuance of the Second Tranche Purchase Shares
at or prior to the Second Tranche Closing.
(x) Delivery
of Irrevocable Transfer Agent Instructions. At the Second Tranche Closing, in accordance with the instructions of the Buyer, the
Company shall have delivered irrevocable instructions to its transfer agent to (i) issue and deliver to the Buyer, within two (2) Business
Days after the Second Tranche Closing, a DRS Statement reflecting the Second Tranche Purchase Shares purchased by the Buyer at the Second
Tranche Closing, which DRS Statement shall not bear any restrictive or other legends and shall be freely tradable and transferable and
without restriction on transfer or (ii) credit the Buyer’s or its designee’s account at DTC through its Deposit/Withdrawal
at Custodian (DWAC) system, within two (2) Business Days after the Second Tranche Closing, with a number of shares of Common Stock equal
to the number of Second Tranche Purchase Shares purchased by the Buyer at the Second Tranche Closing, which shall not bear any restrictive
or other legends and shall be freely tradable and transferable and without restriction on transfer.
(xi) No
Restrictive Legends. If requested by the Buyer in accordance with Section 5.02 hereof, the Company, in accordance with the Buyer’s
instructions, shall have caused its transfer agent to (i) issue and deliver to the Buyer, on or prior to the applicable Legend Removal
Date, one or more certificates or DRS Statements representing the First Tranche Purchase Shares, which are free from all restrictive
and other legends and are freely tradable and transferable and without restriction on resale or (ii) credit the Buyer’s or its
designee’s account at DTC through its Deposit/Withdrawal at Custodian (DWAC) system, on or prior to the applicable Legend Removal
Date, with a number of shares of Common Stock equal to the number of First Tranche Purchase Shares represented by DRS Statements or certificates
containing such restrictive and other legends, which are free from all restrictive and other legends and are freely tradable and transferable
and without restriction on resale.
(xii) No
Material Adverse Effect. No condition, occurrence, state of facts or event constituting a Material Adverse Effect shall have occurred
and be continuing.
(xiii) Current
Public Information. All reports, schedules, registrations, forms, statements, information, and other documents required to have been
filed by the Company with the Commission pursuant to the reporting requirements of the Exchange Act, including all material required
to have been filed pursuant to Section 13(a) or 15(d) of the Exchange Act, shall have been filed with the Commission under the Exchange
Act.
Section 2.07 Exemption from Registration.
The Shares are being offered and sold by the Company to the Buyer pursuant to this Agreement in reliance upon the exemption from the
registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder
(without limiting any other such exemption which may apply to the transactions contemplated by this Agreement) and in reliance upon specific
exemptions from the registration or qualification requirements of applicable state securities laws.
Article III.
Representations and Warranties of the Company
Except as otherwise described
in the Commission Documents or as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and
shall qualify any representations or warranties (or covenants, as applicable) or otherwise made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties
to the Buyer:
Section 3.01 Authorization
of Transactions. The Company is a Delaware corporation and has the requisite corporate power and authority to execute and
deliver this Agreement, the Registration Rights Agreement and to perform its obligations hereunder and thereunder. The execution,
delivery and performance by the Company of this Agreement, the Registration Rights Agreement and the consummation of the
Transactions have been duly and validly authorized by all requisite corporate action on the part of the Company and its
representatives. Each of this Agreement and the Registration Rights Agreement has been (or upon delivery will have been) duly
executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and legally
binding obligation of the Company, enforceable against the Company in accordance with its terms and conditions, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by Laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable Law.
Section 3.02 Governmental
Approvals; Non-Contravention; Subsidiaries; Organization and Qualification.
| (a) | No consent, decree, Order, action or non-action of, filing
(of any kind), except one or more Registration Statements filed with the Commission pursuant to the Registration Rights Agreement, notification,
declaration, affidavit, registration, completion, or any action (in any respect) by any Governmental Entity or Person is necessary for
the execution, delivery or performance by the Company of this Agreement, except any filings that may be required by the rules and regulations
of the Securities and Exchange Commission (the “Commission”), the Principal Market and such filings as are required to be
made under applicable state securities laws. |
| (b) | The execution, delivery and performance
by the Company of this Agreement and the Registration Rights Agreement and the consummation
by the Company of the Transactions, do not: (i) violate or conflict with any applicable Law
or Order to which the Company or any of the Shares may be subject, (ii) constitute a violation
or breach of, be in conflict with, constitute or create (with or without due notice or lapse
of time or both) a default (or give rise to any right of termination, modification, cancellation
or acceleration) of any obligation or right under any Contract to which the Company is a
party or to which the Company or any of the Shares are subject or (iii) result in the creation
or imposition or application of any Lien upon any of the rights, properties, obligations
or assets of the Company or on any of the Shares, in
each case inclusive of or in violation of or in imposition of any such Lien; except, in the
case of clauses (i) and (iii) above, for any such conflict, breach, violation or default
that would not or would not reasonably be expected to result in a Material Adverse Effect. |
| (c) | The Company owns, directly or indirectly,
all the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all the issued and outstanding shares of capital stock of each Subsidiary are
validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded. |
| (d) | The Company and each of the Subsidiaries
is an entity duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business
as currently conducted. Neither the Company nor any Subsidiary is in violation nor default
of any of the provisions of its respective certificate or articles of incorporation, bylaws
or other organizational or charter documents. Each of the Company and the Subsidiaries is
duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or
in good standing, as the case may be, could not have or reasonably be expected to result
in a Material Adverse Effect and no action, claim, suit, investigation or proceeding (including,
without limitation, an informal investigation or partial proceeding, such as a deposition),
whether commenced or threatened has been instituted in any such jurisdiction revoking, limiting
or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. |
Section 3.03 The
Shares. The First Tranche Purchase Shares to be issued and sold to the Buyer at the First Tranche Closing under this Agreement
have been duly authorized by all necessary corporate action on the part of the Company and, when issued and sold at the First
Tranche Closing against payment therefor in accordance with this Agreement, shall be validly issued and outstanding, fully paid and
non-assessable and free from all Liens, and the Buyer shall be entitled to all rights accorded to a holder of Common Stock. The
Second Tranche Purchase Shares to be issued and sold to the Buyer at the Second Tranche Closing under this Agreement shall be duly
authorized at or prior to the Second Tranche Closing by all necessary corporate action on the part of the Company and, when issued
and sold at the Second Tranche Closing against payment therefor in accordance with this Agreement, shall be validly issued and
outstanding, fully paid and non-assessable and free from all Liens, and the Buyer shall be entitled to all rights accorded to a
holder of Common Stock.
Section 3.04 Reporting
Company Status. As of the date of this Agreement and as of each Closing Date, the Common Stock is registered pursuant to Section
12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company has taken no action
designed to, or which to its Knowledge is likely to have the effect of, terminating the registration of the Common Stock under the
Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration. As
of the date of this Agreement and as of each Closing Date, the Common Stock is listed and traded on the Principal Market, and,
except as otherwise disclosed in any Commission Documents, the Company has not received notice from the Principal Market to the
effect that the Company is not in compliance with the listing or maintenance requirements of the Principal Market. As of each
Closing Date, except as otherwise disclosed in any Commission Documents, the Company is in compliance with all such listing and
maintenance requirements. The Common Stock is eligible for participation in the DTC book entry system and has shares on deposit at
DTC for transferred electronically to third parties via DTC through its Deposit/Withdrawal at Custodian delivery system. The Company
has not received notice from DTC to the effect that a suspension of, or restriction on, accepting additional deposits of the Common
Stock, electronic trading, or book-entry services by DTC with respect to the Common Stock is being imposed or is contemplated.
Section 3.05 Commission
Documents; Disclosure.
| (a) | The Company has timely filed (giving
effect to permissible extensions in accordance with Rule 12b-25 under the Exchange Act) all
reports, schedules, registrations, forms, statements, information and other documents filed
with or furnished to the Commission by the Company pursuant to the reporting requirements
of the Exchange Act, including all material filed with or furnished to the Commission pursuant
to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, including, without limitation,
the Annual Report on Form 10-K filed by the Company for its fiscal year ended December 31,
2022 (the “2022 Form 10-K”), for the twelve months preceding the date of this
Agreement (the “Commission Documents”). The Company has delivered or made available
to the Buyer via EDGAR or otherwise true and complete copies of the Commission Documents
filed with or furnished to the Commission prior to the First Tranche Closing Date (including,
without limitation, the 2022 Form 10-K). As of its filing date, each Commission Document
filed with or furnished to the Commission prior to the First Tranche Closing Date (including,
without limitation, the 2022 Form 10-K) complied in all material respects with the requirements
of the Securities Act or the Exchange Act, as applicable, and other federal, state and local
laws, rules and regulations applicable to it, and, as of its filing date (or, if amended
or superseded by a filing prior to the First Tranche Closing Date, on the date of such amended
or superseded filing) and none of the Commission Documents, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company under
the Securities Act or the Exchange Act. |
| (b) | Except with respect to the material
terms and conditions of the transactions contemplated by the Transaction Documents or as
otherwise set forth in the Disclosure Schedules, the Company confirms that neither it nor
any other Person acting on its behalf has provided any of the Buyer or its agents or counsel
with any information that it believes constitutes or might constitute material, non-public
information. The Company understands and confirms that the Buyer will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure
furnished by or on behalf of the Company to the Buyer regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules is true and correct and does not contain any untrue statement of a material fact
or omit to state any material fact necessary in order to make the statements made therein,
in the light of the circumstances under which they were made, not misleading. The press releases
disseminated by the Company since September 15, 2022, taken as a whole, do not contain any
untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under
which they were made and when made, not misleading. The Company acknowledges and agrees that
the Buyer is neither making nor has made any representations or warranties with respect to
the transactions contemplated hereby other than those specifically set forth in the Transaction
Documents. |
Section 3.06 Financial
Statements. The financial statements of the Company included or incorporated by reference in the Commission Documents, together
with the related notes and schedules, comply in all material respects with the requirements of the Securities Act and the Exchange
Act and fairly present the financial condition of the Company as of the dates indicated and the results of operations and changes in
cash flows for the periods therein specified in conformity with generally accepted accounting principles in the United States
(“GAAP”) consistently applied throughout the periods involved; all non-GAAP financial information included or
incorporated by reference in the Commission Documents complies with the requirements of Regulation G and Item 10 of Regulation S-K
under the Securities Act, to the extent applicable; and, except as disclosed in the Commission Documents, there are no material
off-balance sheet arrangements (as defined in Regulation S-K under the Act, Item 303(a)(4)(ii)) or any other relationships with
unconsolidated entities or other persons, that may have a material current or, to the Company’s Knowledge, material future
effect on the Company’s financial condition, results of operations, liquidity, capital expenditures, capital resources or
significant components of revenue or expenses. No other financial statements or schedules are required to be included in the
Commission Documents.
Section 3.07 Disclosure
Controls and Procedures. Except as described in the Commission Documents, the Company maintains a system of “disclosure
controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the
Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and
communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure and such
disclosure controls and procedures are effective in all material respects to perform the functions for which they were established.
The Company has carried out evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of
the Exchange Act.
Section 3.08 Accountants.
To the Company’s Knowledge, KPMG LLP, which has expressed its opinion with respect to the consolidated financial statements as
of December 31, 2022, is (x) an independent public accounting firm within the meaning of the Securities Act, (y) a registered public
accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”)) and (z)
not in violation of the auditor independence requirements of the Sarbanes-Oxley Act.
Section 3.09 Sarbanes-Oxley
Act. There is no failure on the part of the Company or, to the Knowledge of the Company, any of the Company’s directors or
officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act and the rules
and regulations promulgated in connection therewith that are applicable to the Company or its directors or officers in their
capacities as directors or officers of the Company.
Section 3.10 No
Undisclosed Liabilities. Since the date of the latest unaudited financial statements included within the Commission Documents,
the Company has not incurred any liabilities (contingent or otherwise) other than (a) trade payables and accrued expenses incurred
in the ordinary course of business consistent with past practice and (b) liabilities not required to be reflected in the
Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission.
Section 3.11 No
Undisclosed Events or Circumstances. Except as set forth in Section 3.11 of the Disclosure Schedules, since the date of the
latest unaudited financial statements included within the Commission Documents, there has been no event with respect to the Company
that (a) would be required to be disclosed by the Company under applicable securities laws, which has not been so disclosed in
filings made with the Commission, or (b) would reasonably be expected to have a Material Adverse Effect.
Section 3.12 Capitalization;
Indebtedness; Intellectual Property; Insurance.
| a) | The capitalization of the Company as
of the date hereof is as set forth in Section 3.12(a) of the Disclosure Schedules, which
includes the number of shares of Common Stock owned beneficially, and of record, by the executive
officers and directors of the Company as of July 14, 2023. Except as disclosed in the Commission
Documents, the Company has not issued any capital stock since its most recently filed periodic
report under the Exchange Act, other than pursuant to the exercise of employee stock options
under the Company’s stock option plans, the issuance of shares of Common Stock to employees
pursuant to the Company’s employee stock purchase plans and pursuant to the conversion
and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently
filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Other than as a result of the purchase and sale of the Shares
and except as otherwise set forth Section 3.12(a) of the Disclosure Schedules, there are
no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound
to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of
any Subsidiary. The issuance and sale of the Shares will not obligate the Company or any
Subsidiary to issue shares of Common Stock or other securities to any Person (other than
the Buyer). There are no outstanding securities or instruments of the Company or any Subsidiary
with any provision that adjusts the exercise, conversion, exchange or reset price of such
security or instrument upon an issuance of securities by the Company or any Subsidiary. Except
as disclosed in the Commission Documents, there are no outstanding securities or instruments
of the Company or any Subsidiary that contain any redemption or similar provisions, and there
are no contracts, commitments, understandings, or arrangements by which the Company or any
Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
The Company does not have any stock appreciation rights or “phantom stock” plans
or agreements or any similar plan or agreement. All of the outstanding shares of capital
stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws. No further approval
or authorization of any stockholder, the Board of Directors or others is required for the
issuance and sale of the Shares. There are no stockholders agreements, voting agreements
or other similar agreements with respect to the Company’s capital stock to which the
Company is a party or, to the Knowledge of the Company, between or among any of the Company’s
stockholders. |
| b) | The Company’s Quarterly Report
on Form 10-Q for its fiscal quarter ended March 31, 2023, sets forth, as of March 31, 2023,
all outstanding secured and unsecured Indebtedness of the Company, or for which the Company
has commitments through such date. For the purposes of this Agreement, “Indebtedness”
shall mean (a) any liabilities for borrowed money or amounts owed in excess of $100,000 (other
than trade accounts payable incurred in the ordinary course of business and loans between
the Company and any Subsidiary), (b) all guaranties, endorsements and other contingent obligations
in respect of Indebtedness of others in excess of $100,000, whether or not the same are or
should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (c) the present value of any lease payments in excess
of $100,000 due under leases required to be capitalized in accordance with GAAP. There is
no existing or continuing default or event of default in respect of any Indebtedness of the
Company. |
| c) | The Company and the Subsidiaries have,
or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their
respective businesses as described in the Commission Documents and which the failure to so
have could have a Material Adverse Effect (collectively, the “Intellectual Property
Rights”). To the Knowledge of the Company, none of, and neither the Company nor
any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated, or been abandoned, or is expected to expire or terminate
or be abandoned, within two (2) years from the date of this Agreement. Neither the Company
nor any Subsidiary has received, since the date of the latest audited financial statements
included within the Commission Documents, a written notice of a claim or otherwise has any
Knowledge that the Intellectual Property Rights violate or infringe upon the rights of any
Person, except as could not have or reasonably be expected not to have a Material Adverse
Effect. To the Knowledge of the Company, all such Intellectual Property Rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property
Rights. The Company and its Subsidiaries have taken reasonable security measures to protect
the secrecy, confidentiality, and value of all of their intellectual properties, except where
failure to do so could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect. |
| d) | The Company and the Subsidiaries are
insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as are prudent and customary in the businesses in which the Company and
the Subsidiaries are engaged. |
Section 3.13 Actions
Pending. Except for any Action (as defined below) described in the Commission Documents, there is no action, suit, inquiry,
proceeding or investigation pending before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an “Action”), to which the Company is a party
or to which any of the properties of the Company is subject, that (a) challenges the validity of any of the Transaction Documents or
the Transactions or (b) would reasonably be expected to result in a Material Adverse Effect. The Commission has not issued any stop
order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the
Exchange Act or the Securities Act.
Section 3.14 Permits;
Compliance with Law; Compliance with Agreements; Compliance with Listing Standards. The Company and the Subsidiaries possess all
certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary
to conduct their respective businesses as described in the Commission Documents, except where the failure to possess such permits
could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the
Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.
The business of the Company has been and is presently being conducted in compliance with all applicable federal, state, local and
foreign governmental laws, rules, regulations, and ordinances, except as set forth in the Commission Documents and except for such
non-compliance which, individually or in the aggregate, would not have a Material Adverse Effect. The Company is not in default
under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would
result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that
it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument
to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived).
The Company is not in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the
Company, and the Company will not conduct its business in violation of any of the foregoing, except in all cases for any such
violations which could not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in the Commission
Documents, the Company has not received any written notice of any continuing failure to maintain requirements for continued listing
or quotation of its Common Stock on the Principal Market or in violation of any of the rules, regulations, or requirements of the
Principal Market.
Section 3.15 Investment
Company Act. The Company is not, and as a result of the consummation of the Transactions and the application of the proceeds
from the sale of the Shares as will be set forth in the prospectus included in any Registration Statement (and any post-effective
amendment thereto) filed pursuant to the Registration Rights Agreement the Company will not be an “investment company”
within the meaning of the Investment Company Act of 1940, as amended.
Section 3.16 Exemption
from Registration; No General Solicitation or Advertising; No Integrated Offering; Disqualification Events. Assuming the
accuracy of the representations, warranties and covenants made herein by the Buyer in Article IV hereof, the offer and sale of the
Shares by the Company to the Buyer in accordance with the terms and conditions of this Agreement is exempt from the registration
requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder. Neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection with the
offer or sale of the Shares. None of the Company or any of its Affiliates, nor any Person acting on their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would
require registration of the issuance of any of the Shares under the Securities Act, whether through integration with prior offerings
or otherwise, or cause this offering of the Shares to require approval of stockholders of the Company under any applicable
stockholder approval provisions, including, without limitation, under the rules and regulations of the Principal Market. None of the
Company, its Subsidiaries, their Affiliates nor any Person acting on their behalf will take any action or steps referred to in the
preceding sentence that would require registration of the issuance of any of the Shares under the Securities Act or cause the
offering of any of the Shares to be integrated with other offerings. With respect to the Shares to be offered and sold hereunder in
reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the
Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is
defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an
“Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to any of the
“Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a
“Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company
has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has
complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Buyer a copy of any
disclosures provided thereunder.
Section 3.17 Securities
Act; Blue Sky Laws. The Company has complied with all applicable federal and state securities laws in connection with the offer,
issuance, and sale of the Shares hereunder, including, without limitation, the applicable requirements of the Securities Act. The
Company shall take such action as is reasonably necessary in order to obtain an exemption for, or to qualify the Shares for sale to
the Buyer pursuant to this Agreement under applicable state securities or “Blue Sky” laws (or to obtain an exemption
from such qualification), and shall provide evidence of any such action so taken to the Buyer. Each Registration Statement, upon
filing with the Commission and at the time it is declared effective by the Commission, shall satisfy all of the requirements of the
Securities Act to register the resale of the Registrable Securities (as defined in the Registration Rights Agreement) included
therein by the Buyer in accordance with the Registration Rights Agreement on a delayed or continuous basis under Rule 415 under the
Securities Act at then-prevailing market prices, and not fixed prices. The Company is not, and has not previously been at any time,
an issuer identified in, or subject to, Rule 144(i) under the Securities Act.
Section 3.18 No
Manipulation of Price. Neither the Company nor any of its officers, directors or Affiliates has, and, to the Knowledge of the
Company, no Person acting on their behalf has, (i) taken, directly or indirectly, any action designed or intended to cause or to
result in the stabilization or manipulation of the price of any security of the Company, or which caused or resulted in, or which
would in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of
the Company, in each case to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any
compensation for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for
soliciting another to purchase any other securities of the Company. Neither the Company nor any of its officers, directors or
Affiliates will during the term of this Agreement, and, to the Knowledge of the Company, no Person acting on their behalf will
during the term of this Agreement, take any of the actions referred to in the immediately preceding sentence.
Section 3.19 Arm’s
Length Status of Buyer; Acknowledgement Regarding Buyer’s Trading Activity. Section 3.20 The Company acknowledges and
agrees that the Buyer is acting solely in the capacity of an arm’s-length purchaser with respect to this Agreement, the
Registration Rights Agreement, and the Transactions. The Company further acknowledges that the Buyer is not acting as a financial
advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement, the Registration Rights Agreement
and the Transactions, and any advice given by the Buyer or any of its representatives or agents in connection therewith is merely
incidental to the Buyer’s acquisition of the Shares. The Company further represents to the Buyer that the Company’s
decision to enter into this Agreement has been based solely on the independent evaluation of the Transactions contemplated thereby
by the Company and its representatives. The Company acknowledges and agrees that the Buyer has not made and does not make any
representations or warranties with respect to the Transactions, other than those made in the Transaction Documents. Anything
in this Agreement or elsewhere herein to the contrary notwithstanding, it is understood and acknowledged by the Company that: (i)
the Buyer has neither been asked by the Company to agree, nor has the Buyer agreed, to desist from purchasing or selling, long
and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold
the Securities for any specified term, (ii) past or future open market or other transactions by the Buyer, specifically including,
without limitation, Short Sales or “derivative” transactions, before or after the closing of this or future private
placement transactions, may negatively impact the market price of the Company’s publicly-traded securities, (iii) the Buyer,
and counter-parties in “derivative” transactions to which the Buyer is a party, directly or indirectly, may presently
have a “short” position in the Common Stock and (iv) the Buyer shall not be deemed to have any affiliation with or
control over any arm’s length counter-party in any “derivative” transaction solely as a result of such derivative
transaction. The Company further understands and acknowledges that (y) the Buyer may engage in hedging activities at various
times during the period that the Shares are outstanding, including, without limitation, during the periods that the value of the
Shares deliverable are being determined, and (z) such hedging activities (if any) could reduce the value of the existing
stockholders’ equity interests in the Company at and after the time that the hedging activities are being conducted. The
Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.
Section 3.20 [Intentionally
Omitted].
Section 3.21 Brokers.
Except as set forth in Section 3.21 of the Disclosure Schedules, the Company has not engaged any investment banker, finder, broker or
sales agent or any other Person in connection with the origin, negotiation, execution, delivery or performance of this Agreement or the
Transactions.
Article IV.
Representations and Warranties of the Buyer
The Buyer represents and
warrants to the Company that the following statements contained in this Article IV are true and correct as of the date of this Agreement
and as of each Closing Date:
Section 4.01 Authorization
of Transactions. The Buyer is a corporation, duly organized and in good standing under the laws of the State of Delaware and has
the requisite power and capacity to execute and deliver this Agreement and the Registration Rights Agreement and to perform its
obligations hereunder and thereunder. The execution, delivery and performance by the Buyer of this Agreement and the Registration
Rights Agreement and the consummation of the Transactions have been duly and validly authorized by all requisite action on the part
of the Buyer. Each of this Agreement and the Registration Rights Agreement has been duly and validly executed and delivered by the
Buyer and constitutes the valid and legally binding obligation of the Buyer, enforceable against the Buyer in accordance with its
terms and conditions, except to the extent enforcement thereof may be limited by applicable bankruptcy, insolvency or other Laws
affecting the enforcement of creditors’ rights or by the principles governing the availability of equitable remedies.
Section 4.02 Governmental
Approvals; Non-contravention.
| (a) | No consent, Order, action or non-action
of, or filing, notification, declaration or registration with, any Governmental Entity is
necessary for the execution, delivery or performance by the Buyer of this Agreement and the
Registration Rights Agreement. |
| (b) | The execution, delivery and performance
by Buyer of this Agreement and the Registration Rights Agreement and the consummation by
Buyer of the Transactions do not violate any Laws or Orders to which Buyer is subject or
any of the organizational documents of the Buyer. |
Section 4.03 No
Consent, Violation or Conflict. The execution and delivery of this Agreement and the Registration Rights Agreement by the Buyer,
the consummation by the Buyer of the Transactions, and compliance by the Buyer with the provisions hereof: (a) do not and will not
violate or, if applicable, conflict with any provision of Law, or any provision of the Buyer’s certificate of incorporation or
bylaws; and (b) do not and will not, with or without the passage of time or the giving of notice, result in the breach of, cause the
acceleration of performance or constitute a default or require any consent under, any material instrument or agreement to which the
Buyer is a party or by which the Buyer or its properties may be bound or affected, other than instruments or agreements as to which
consent shall have been obtained at or prior to the Closing Date or any breaches or defaults which would not affect the
Buyer’s ability to consummate the transactions contemplated thereby.
Section 4.04 Investment
Representations.
| (a) | The Buyer understands and agrees that
the consummation of this Agreement including the delivery of the Shares to the Buyer as contemplated
hereby constitutes the offer and sale of securities under the Securities Act and applicable
state statutes and that the Shares are being acquired for Buyer’s own account and not
with a present view towards the public sale or distribution thereof, except pursuant to sales
registered or exempted from registration under the Securities Act. |
| (b) | The Buyer is an “accredited investor”
as that term is defined in Regulation D Rule 501(a) under the Securities Act (an “Accredited
Investor”). |
| (c) | The Buyer, either alone or together
with its representatives and/or advisors, has such knowledge, sophistication, and experience
in business and financial matters so as to be capable of evaluating the merits and risks
of the prospective investment in the Shares and has evaluated the merits and risks of the
proposed investment. The Buyer is able to bear the economic risk of an investment in the
Shares and, at the present time, is able to afford a complete loss of such investment. |
| (d) | The Buyer understands that the Shares
are being offered and sold to the Buyer in reliance upon specific exemptions from the registration
requirements of the Securities Act and state securities laws and that the Company is relying
upon the truth and accuracy of, and the Buyer’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Buyer set forth herein
in order to determine the availability of such exemptions and the eligibility of Buyer to
acquire the Shares. |
| (e) | Buyer and its advisors, if any, have
been furnished with all materials relating to the business, finances and operations of the
Company and materials relating to the offer and sale of the Shares which have been requested
by the Buyer or its advisors. The Buyer and its advisors, if any, have been afforded the
opportunity to ask questions of the Company. The Buyer is aware that an investment in the
Shares involves several very significant risks and has carefully researched and reviewed
and understands the risks of, and other considerations relating to the purchase of the Shares. |
| (f) | Buyer has adequate means of providing
for the Buyer’s current financial needs and foreseeable contingencies and has no need
for liquidity of its investment in the Shares for an indefinite period of time, and after
purchasing the Shares, the Buyer will be able to provide for any foreseeable current needs
and possible personal contingencies. The Buyer must bear and acknowledges the substantial
economic risks of the investment in the Shares including the risk of illiquidity and is able
to afford the complete loss of its investment in the Shares. |
| (g) | The Buyer understands that no United
States federal or state agency or any other government or governmental agency has passed
upon or made any recommendation or endorsement of the Shares. |
| (h) | The Buyer understands that except as
otherwise set forth herein: (i) the Shares have not been and are not being registered under
the Securities Act or any state or foreign securities laws, and may not be offered for sale,
sold, assigned or transferred unless (A) subsequently registered thereunder, or (B) the Buyer
shall have delivered to the Company an opinion of counsel, in a form generally acceptable
to the Company, to the effect that such securities to be sold, assigned or transferred may
be sold, assigned or transferred pursuant to an exemption from such registration requirements;
(ii) any sale of such securities made in reliance on Rule 144 under the Securities Act (or
a successor rule thereto) (“Rule 144”) may be made only in accordance
with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of such
securities under circumstances in which the seller (or the person through whom the sale
is made) may be deemed to be an underwriter (as that term is defined in the Securities Act)
may require compliance with some other exemption under the Securities Act or the rules and
regulations of the Commission thereunder; and (iii) other than as set forth in this Agreement
and the Registration Rights Agreement, neither the Company nor any other person is under
any obligation to register such securities under the Securities Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder. There can be
no assurance that there will be any market or resale for the Shares, nor can there be any
assurance that the Shares will be freely transferable at any time in the foreseeable future. |
| (i) | The Buyer is not purchasing the Shares
as a result of any “General Solicitation” (as defined in Regulation D) including,
but not limited to, any advertisement, article, notice or other communication regarding the
Shares published in any newspaper, magazine or similar media or broadcast over television
or radio or presented at any seminar or, to the knowledge of the Buyer, any other general
solicitation or general advertisement. |
| (j) | The Buyer understands that, except as
set forth in Section 5.02 of this Agreement, the certificates or other instruments representing
the Shares shall bear a restrictive legend in substantially the following form (and a stop
transfer order may be placed against transfer of such Shares): |
THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THESE
SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) IN COMPLIANCE WITH RULE 144 OR 144A THEREUNDER,
IF AVAILABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (C) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT, OR (D) IN
A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS, AND THE HOLDER HAS,
PRIOR TO SUCH SALE, FURNISHED TO THE COMPANY AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE REASONABLY SATISFACTORY
TO THE COMPANY. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.
| (k) | The Buyer is not a director or executive
officer of the Company, a beneficial owner of ten percent (10%) or more of the Company’s
outstanding voting equity securities, calculated on the basis of voting power, nor a promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of sale of the Shares and is not subject to any of the “Bad
Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities
Act (a “Disqualification Event”), except for a Disqualification Event covered
by Rule 506(d)(2) or (d)(3). |
Section 4.05 Brokers.
The Buyer has not engaged any investment banker, finder, broker or sales agent or any other Person in connection with the origin,
negotiation, execution, delivery or performance of this Agreement or the Transactions.
Article V. Indemnification;
Additional Covenants
Section 5.01 Indemnification.
In consideration of the Buyer’s execution and delivery of this Agreement and acquiring the Shares hereunder and in addition to
all of the Company’s other obligations under this Agreement and the Registration Rights Agreement, the Company shall defend, protect,
indemnify and hold harmless the Buyer and each holder of any Shares and all of their stockholders, partners, members, officers, directors,
employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives (including, without
limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses
in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is
sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any
Indemnitee as a result of, or arising out of, or relating to: (a) any misrepresentation or breach of any representation or warranty made
by the Company in this Agreement or the Registration Rights Agreement, (b) any breach of any covenant, agreement or obligation of the
Company contained in this Agreement or the Registration Rights Agreement or (c) any cause of action, suit or claim brought or made against
such Indemnitee by a third party (including for these purposes a derivative action brought on behalf of the Company) and arising out
of or resulting from (i) the execution, delivery, performance or enforcement of this Agreement or the Registration Rights Agreement or
(ii) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance and sale
of the Shares to the Buyer pursuant to this Agreement; provided, however, that (x) the Company shall not be liable to any Indemnitee
under subsection (c) of this Section 5.01 to the extent, and only to the extent, that a court of competent jurisdiction shall have determined
by a final judgment (from which no further appeals are available) that such Indemnified Liabilities resulted directly and primarily from
any acts or failures to act undertaken or omitted to be taken by the Buyer through its bad faith or willful misconduct, (y) the forgoing
indemnity shall not apply to any Indemnified Liabilities to the extent, and only to the extent, that such Indemnified Liabilities resulted
directly and primarily from a breach of any of the Buyer’s representations, warranties, covenants or agreements contained in this
Agreement, and (z) the Company shall not be liable under this Section 5.01 for any settlement by an Indemnitee effected without the Company’s
prior written consent, which shall not be unreasonably withheld or delayed. The Company shall reimburse any Indemnitee promptly upon
demand (with accompanying presentation of documentary evidence) for all legal and other costs and expenses reasonably incurred by such
Indemnitee in connection with: (i) any action, suit, claim or proceeding, whether at law or in equity, to enforce compliance by the Company
with any provision of this Agreement or the Registration Rights Agreement or (ii) any other any action, suit, claim or proceeding, whether
at law or in equity, with respect to which it is entitled to indemnification under this Section 5.01; provided that an Indemnitee shall
promptly reimburse the Company for all such legal and other costs and expenses to the extent a court of competent jurisdiction shall
have determined by a final judgment (from which no further appeals are available) that such Indemnitee was not entitled to such reimbursement.
An Indemnitee’s right to indemnification or other remedies based upon the representations, warranties, covenants and agreements
of the Company set forth in this Agreement or the Registration Rights Agreement shall not in any way be affected by any investigation
or knowledge of such Indemnitee. Such representations, warranties, covenants and agreements shall not be affected or deemed waived by
reason of the fact that an Indemnitee knew or should have known that any representation or warranty might be inaccurate or that the Company
failed to comply with any agreement or covenant. Any investigation by such Indemnitee shall be for its own protection only and shall
not affect or impair any right or remedy hereunder. To the extent that the foregoing undertaking by the Company may be unenforceable
for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities
which is permissible under applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the rights
and obligations under this Section 5.01 shall be the same as those set forth in Section 5 of the Registration Rights Agreement. Notwithstanding
anything to the contrary in this Section 5.01, the Company shall not be obligated to pay an Indemnitee any sums otherwise due under this
Section 5.01 if the Company has already paid the Indemnitee such sums for the same Indemnified Liabilities under Section 5 of the Registration
Rights Agreement.
Section 5.02 Legend Removal;
Delivery Failure. The Company shall use its best efforts to cause its transfer agent to remove the legend set forth and referred
to in Section 4.04(j) of this Agreement from the Shares and to issue a certificate without such legend to the holder of the Shares upon
which it is stamped, or to issue to such holder by electronic delivery at the applicable balance account at DTC, unless otherwise required
by state securities or “blue sky” laws, at such time as: (i) the resale of such Shares is registered under the Securities
Act under an effective registration statement, (ii) the Buyer shall have delivered to the Company an opinion of counsel, in a form reasonably
acceptable to the Company, to the effect that such Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant
to an exemption from such registration requirements; or (iii) if such Shares are eligible to be sold under Rule 144, the Buyer provides
the Company with reasonable assurance in writing that the Shares are being sold, assigned or transferred pursuant to Rule 144 (which
shall not include an opinion of Buyer’s counsel). In furtherance of the foregoing, the Company agrees that, following the effective
date of the initial Registration Statement to be filed by the Company with the Commission pursuant to the Registration Rights Agreement,
or at such time as such legend is not required to be placed upon certificates representing the Shares as set forth in Section 4.04(h)
or this Section 5.02, the Company shall, no later than two (2) Business Days following the delivery by the Buyer to the Company or its
transfer agent of (i) a certificate representing Shares issued with a restrictive legend (such second (2nd) Trading Day, the
“Legend Removal Date”) and (ii) customary representations and other documentation reasonably acceptable to the Company and
its transfer agent in connection therewith, either: (A) issue and deliver (or cause to be issued and delivered) to the Buyer a certificate
or DRS Statement representing such Shares that is free from all restrictive and other legends or (B) cause its transfer agent to credit
the Buyer’s or its designee’s account at DTC through its Deposit/Withdrawal at Custodian (DWAC) system with a number of shares
of Common Stock equal to the number of Shares represented by the certificate so delivered by the Buyer. If the Company fails on or prior
to the Legend Removal Date (other than any such failure that is solely due to any action or inaction by the Holder) to either (i) issue
and deliver (or cause to be issued and delivered) to the Buyer a certificate or DRS Statement representing the Shares that is free from
all restrictive and other legends or (ii) cause its transfer agent to credit the balance account of the Buyer or its designee at DTC
through its Deposit/Withdrawal at Custodian (DWAC) system with a number of shares of Common Stock equal to the number of the Shares represented
by the certificate delivered by the Buyer pursuant hereto (a “Delivery Failure”), and if on or after the Legend Removal Date
the Buyer purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Buyer
of shares of Common Stock that the Buyer anticipated receiving from the Company without any restrictive legend, then the Company shall,
within two (2) Business Days after the Buyer’s request, pay cash to the Buyer in an amount equal to the Buyer’s total purchase
price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company’s obligation
to deliver a certificate or credit the Buyer’s or its designee’s account at DTC for such shares of Common Stock shall terminate
and such shares shall be cancelled.
Section 5.03 Termination.
In the event that the First Tranche Closing shall not have occurred within ten (10) days after the date of this Agreement, then the
Buyer shall have the right to terminate its obligations under this Agreement at any time on or after the close of business on such
date without liability of the Buyer to any other Party; provided, however, the right to terminate its obligations under this
Agreement pursuant to this first sentence of Section 5.03 shall not be available to the Buyer if the failure of the First Tranche
Closing to have occurred by such date is the result of the Buyer’s breach of this Agreement. In the event the Buyer is in
breach in any material respect under any of the provisions of this Agreement or the Registration Rights Agreement, and, if such
breach is capable of being cured, such breach is not cured within ten (10) Business Days after notice of such breach is delivered to
the Buyer pursuant to Section 6.01 hereof, then the Company shall have the right to terminate its obligations to issue the Second
Tranche Purchase Shares under this Agreement at any time thereafter and prior to the Second Tranche Closing without liability of the
Company to any other Party. In the event the Initial Registration Statement is not filed by the applicable Filing Deadline (as
defined in the Registration Rights Agreement) therefor or declared effective by the Commission by the applicable Effective Date (as
defined in the Registration Rights Agreement) therefor, or the Company is otherwise in breach or default in any material respect
under any of the other provisions of this Agreement or the Registration Rights Agreement, and, if such failure, breach or default is
capable of being cured, such failure, breach or default is not cured within ten (10) Business Days after notice of such failure,
breach or default is delivered to the Company pursuant to Section 6.01 hereof, then the Buyer shall have the right to terminate its
obligations to purchase the Second Tranche Purchase Shares under this Agreement at any time thereafter and prior to the Second
Tranche Closing without liability of the Buyer to any other Party; provided, however, the right to terminate its obligations under
this Agreement pursuant to this second sentence of Section 5.03 shall not be available to the Buyer if the failure of the
Registration Statement to be filed by the applicable Filing Deadline or declared effective by the applicable Effective Date therefor
is the result of the Buyer’s breach of this Agreement or the Registration Rights Agreement. Nothing contained in this Section
5.03 shall be deemed to release any Party from any liability for any breach by such party of the terms and provisions of this
Agreement or the Registration Rights Agreement or to impair the right of any Party to compel specific performance by any other Party
of its obligations under this Agreement or the Registration Rights Agreement.
Section 5.04 Purchase Price
Penalty.
| (a) | From the First Tranche Closing Date
until ten (10) days after the effective date of the Initial Registration Statement (as defined
in the Registration Rights Agreement) filed pursuant to the Registration Rights Agreement
(the “Restricted Period”), if the Company issues or sells any shares of Common
Stock less than the Per Share Price (a “Share Dilutive Issuance”), except for
Exempt Issuances, then the Company shall, within two (2) business days after such Share Dilutive
Issuance, pay to Buyer as a penalty an amount in cash equal to the number of Shares theretofore
purchased by Buyer hereunder multiplied by the difference between (A) the Per Share Price
and (B) the greater of (i) the price per share of Common Stock paid in the Share Dilutive
Issuance and (ii) the Floor Price. For purposes of this Agreement, the Floor Price shall
be $0.02. |
| (b) | For purposes of this Agreement, “Exempt
Issuances” means: (i) Company securities issued or issuable upon a stock split, stock
dividend, or any subdivision of Company securities; (ii) Common Stock or Common Stock Equivalents
issued pursuant to or in connection with any other agreement or arrangement between the Company
and the Buyer at any time prior to or after the date of this Agreement, or upon conversion,
exercise or exchange of any Common Stock Equivalents held by the Buyer or any of its Affiliates
at any time prior to or after the date of this Agreement; (iii) Company securities issued
or issuable as full or partial consideration in connection with a strategic merger, acquisition,
exchange, consolidation or purchase of substantially all of the securities or assets of a
corporation or other entity so long as such issuances are not for the purpose of raising
capital and which holders of such securities or debt are not at any time granted registration
rights to register such securities during the Restricted Period; (iv) the Company’s
issuance of securities in connection with strategic license agreements and other partnering
arrangements so long as such issuances are not for the purpose of raising capital and which
holders of such securities or debt are not at any time granted registration rights; (v) the
Company’s issuance of securities upon the exercise or exchange of or conversion of
any securities exercisable or exchangeable for or convertible into shares of Common Stock
or other Common Stock Equivalents issued and outstanding and on the terms in effect on the
First Tranche Closing Date; (vi) the Company’s issuance of shares of Common Stock or
Common Stock Equivalents, to any investor participating in a private placement of the Company’s
securities (including a Buyer hereof) who (A) was a holder of Assumed Warrants or PIK Notes
as of the commencement of the Exchange Offer or the PIK Note Offer to Amend, as applicable
or (B) is a former holder of 2022 Bridge Debentures, as further consideration for participating
in such private placement, in addition to the equity purchase price and other terms of such
private placement offered to all investors (capitalized terms used in this clause (vi) and
not defined in this Agreement shall have the meanings ascribed to them in Section 3.12(a)
of the Disclosure Schedules); (vii) the Company’s issuance of shares of Common Stock
or Common Stock Equivalents to any former holder of 2022 Bridge Debentures (as defined in
Section 3.12(a) of the Disclosure Schedules) pursuant to a general release agreement; and
(viii) the Company’s issuance of shares of Common Stock or Common Stock Equivalents
to employees, consultants, officers or directors of the Company pursuant to any stock or
option plan duly adopted for such purpose, by a majority of the Board of Directors or a majority
of the members of a committee established for such purpose for services rendered to the Company.
For purposes of this Agreement, “Common Stock Equivalents” means any securities
of the Company which would entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock. |
| (c) | In each case of any penalty due hereunder
as a result of a Share Dilutive Issuance or otherwise, the Company, at its expense, will
promptly (but in no event more than one (1) Business Day after a Share Dilutive Issuance
or other event requiring adjustment or readjustment in the Shares) cause its Chief Financial
Officer or other appropriate designee to compute such penalty in accordance with the terms
hereof, and prepare and deliver to the Buyer in accordance with Section 6.01 hereof a certificate
setting forth such penalty and showing in detail the facts upon which such penalty is based,
including a statement of the price per share of the shares of Common Stock sold in the Dilutive
Issuance and the cash payment to be received by Buyer. |
Section 5.05 Subsequent
Issuances. From the date hereof until ten (10) days after the effective date of the Initial Registration Statement, neither the Company
nor any Subsidiary shall issue or sell, enter into any agreement to issue or sell, or announce the issuance or sale or proposed issuance
or sale of any or Common Stock Equivalents nor shall the Company issue or sell, enter into any agreement to issue or sell, or announce
the issuance or sale or proposed issuance or sale of any shares of Common Stock, pursuant to which shares of Common Stock may be acquired
at a per share price less than the Floor Price, except for (a) Exempt Issuances or (b) the filing of a registration statement so long
as such registration statement is not declared effective by the Commission during the period from the date hereof until ten (10) days
after the effective date of the Initial Registration Statement.
Section 5.06 Principal Market
Adjustments. In the event that the Principal Market shall have any objection to the terms of this Agreement, the parties agree to
adjust the terms of this Agreement necessary to comply with the requirements of the Principal Market.
Article VI.
Miscellaneous
Section 6.01 Notices.
| (a) | Any notice or other communications required
or permitted hereunder shall be in writing and shall be sufficiently given if personally
delivered to it or sent by email, overnight courier or registered mail or certified mail,
postage prepaid, addressed as follows: |
If to the Company, to:
FOXO Technologies
Inc.
Attn: Tyler Danielson,
Interim CEO
729 N. Washington
Ave., Suite 600
Minneapolis, MN
55401
Email: tdanielson@foxotechnologies.com
If to the Buyer, to the address
set forth on the Buyer’s signature page of this Agreement.
| (b) | Any Party may change its address for
notices hereunder upon notice to each other Party in the manner for giving notices hereunder. |
| (c) | Any notice hereunder shall be deemed
to have been given: (i) upon receipt, if personally delivered; (ii) on the day after dispatch,
if sent by overnight courier; (iii) upon dispatch, if transmitted by email with return receipt
requested and received; and (iv) three (3) business days after mailing, if sent by registered
or certified mail. |
Section 6.02 Attorneys’
Fees. In the event that any Party institutes any action or suit to enforce this Agreement or to secure relief from any default
hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party for all costs, including reasonable
attorney’s fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.
Section 6.03 Amendments
and Waivers. No provision of this Agreement may be amended other than by a written instrument signed by both Parties hereto. No
provision of this Agreement may be waived other than in a written instrument signed by the Party against whom enforcement of such
waiver is sought; provided, however, that the failure of the Company to satisfy the conditions precedent to the Second Tranche
Closing set forth in Section 2.06(b) of this Agreement may not be waived by the Buyer. No failure or delay in the exercise of any
power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power,
right or privilege preclude other or further exercises thereof or of any other right, power or privilege.
Section 6.04 No
Third-Party Beneficiaries. Except as expressly provided in Article V, this Agreement is intended only for the benefit of the
Parties hereto and their respective successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced
by, any other Person.
Section 6.05 Expenses.
Unless otherwise contemplated or stipulated by this Agreement, all costs and expenses incurred in connection with this Agreement
shall be paid by the Party incurring such cost or expense.
Section 6.06 Further
Assurances. Following the First Tranche Closing, each Party shall execute and deliver such documents and other papers and take
such further action as may be reasonably required to carry out the provisions of this Agreement.
Section 6.07 Successors
and Assigns; Benefit. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior
written consent of the Buyer (which may be granted or withheld in the sole discretion of the Buyer), provided, however, that Company
may assign its rights or delegate its obligations, in whole or in part, without such consent to an entity that acquires all or
substantially all of the business or assets of such party to which this Agreement pertains, whether by merger, reorganization,
acquisition, sale, or otherwise. The Buyer may assign some or all of its rights hereunder in connection with any assignment or
transfer of any of its Shares without the consent of the Company, in which event such assignee or transferee (as the case may be)
shall be deemed to be the Buyer hereunder with respect to such assigned rights. Nothing in this Agreement, expressed or implied,
shall confer on any Person other than the Parties, and their respective successors and assigns, any rights, remedies, obligations,
or Liabilities under or by reason of this Agreement.
Section 6.08 Governing Law;
Etc.
| (a) | This Agreement, and all matters based
upon, arising out of or relating in any way to the Transactions, including all disputes,
claims or causes of action arising out of or relating to the Transactions or this Agreement,
as well as the interpretation, construction, performance and enforcement of this Agreement,
shall be governed by the laws of the State of New York, without regard to any jurisdiction’s
conflict-of-laws principles. |
| (b) | EACH PARTY HERETO HEREBY WAIVES, TO
THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY
IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS, THE PERFORMANCE THEREOF OR THE FINANCINGS CONTEMPLATED THEREBY (WHETHER
BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS Section 6.08(b). |
| (c) | Each of the Parties acknowledge that
each has had the opportunity to consult with independent legal counsel in connection with
the signing of the waiver in Section 6.08(b) selected by the respective Party. Each of the
Parties further acknowledge that each has read and understands the meaning of such waiver
and grants such waiver knowingly, voluntarily, without duress. |
Section 6.09 Survival.
The representations, warranties, covenants and agreements of the Company and the Buyer contained in this Agreement shall survive the
execution and delivery hereof until the termination of this Agreement; provided, however, that (i) the provisions of Article III
(Representations and Warranties of the Company), Article V (Indemnification; Additional Covenants) (excluding Sections 5.02, 5.04
and 5.05), and this Article VI (Miscellaneous) shall remain in full force and effect indefinitely notwithstanding such termination,
and, (ii) so long as the Buyer owns any Shares, the covenants and agreements of the Company contained in Section 5.02 (Legend
Removal), Section 5.04 (Penalty), and Section 5.05 (Subsequent Issuance) shall remain in full force and effect notwithstanding such
termination.
Section 6.10 Severability.
If any provision of this Agreement is invalid, illegal, or incapable of being enforced by any rule of law or public policy, all
other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or
legal substance of the Transactions is not affected in any manner adverse to any Party. Upon such determination that any provision
is invalid, illegal, or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to
affect the original intent of the Parties as closely as possible in an acceptable manner to the end that the Transactions are
fulfilled to the extent possible.
Section 6.11 Entire
Agreement. This Agreement constitute the entire agreement between the Parties with respect to the subject matter hereof and
thereof and supersedes all prior agreements and understandings, both oral and written, between the Parties with respect to the
subject matter hereof and thereof.
Section 6.12 Remedies
Cumulative; Specific Performance. Each Party’s remedies provided in this Agreement, including, without limitation, the
Buyer’s remedies provided in Section 5.01, shall be cumulative and in addition to all other remedies available to such Party
under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief), no remedy of
such Party contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein
shall limit such Party’s right to pursue actual damages for any failure by the other Party to comply with the terms of this
Agreement. The Company and the Buyer acknowledge and agree that irreparable damage would occur in the event that any of the
provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is
accordingly agreed that either Party shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions
of this Agreement by the other Party and to enforce specifically the terms and provisions hereof (without the necessity of showing
economic loss and without any bond or other security being required), this being in addition to any other remedy to which either
Party may be entitled by law or equity.
Section 6.13 Construction.
The table of contents and headings contained in this Agreement are for reference purposes only and will not affect in any way the
meaning or interpretation of this Agreement. In the event of a conflict between language or amounts contained in the body of this
Agreement and language or amounts contained in any Exhibits attached hereto, the language or amounts in the body of the Agreement
shall control. Any reference in this Agreement to gender shall include all genders, and words imparting the singular number only
shall include the plural and vice versa. The use of the terms “including” or “include” shall in all cases
herein mean “including, without limitation,” or “include, without limitation,” respectively. Reference to
any Person includes such Person’s predecessors, successors and assigns to the extent, in the case of successors and assigns,
such successors and assigns are permitted by the terms of any applicable agreement, and reference to a Person in a particular
capacity excludes such Person in any other capacity or individually. Reference to any agreement (including this Agreement), document
or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance with
the terms thereof and, if applicable, the terms hereof. Reference to any Law means such Law as amended, modified, codified, replaced
or re-enacted, in whole or in part, including rules, regulations, enforcement procedures and any interpretations promulgated
thereunder. Each and every reference to share prices, shares of Common Stock (including, without limitation the First Tranche
Purchase Shares, Second Tranche Purchase Shares, and Shares) and any other numbers in this Agreement that relate to the Common Stock
(including, without limitation the First Tranche Purchase Shares, Second Tranche Purchase Shares, and Shares) shall be automatically
adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions that occur with
respect to the Common Stock after the date of this Agreement. Underscored references to Articles, Sections or Schedules shall refer
to those portions of this Agreement. The use of the terms “hereunder,” “hereof,” “hereto” and
words of similar import shall refer to this Agreement as a whole and not to any particular Article, Section or clause of or Exhibit,
Annex or Schedule to this Agreement.
Section 6.14 Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each Party and delivered to the other Party; provided that a
facsimile signature or signature delivered by e-mail in a “.pdf” format data file, including any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due
execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original
signature.
Section 6.15 Publicity.
The Company shall afford the Buyer and its counsel with the opportunity to review and comment upon, shall consult with the Buyer and
its counsel on the form and substance of, and shall give due consideration to all such comments from the Buyer or its counsel on,
any press release, Commission filing or any other public disclosure by or on behalf of the Company relating to the Buyer, its
purchases of Shares hereunder or any aspect of this Agreement or the Registration Rights Agreement or the Transactions, not less
than six (6) hours prior to the issuance, filing or public disclosure thereof.
[Signature Page Follows]
IN WITNESS WHEREOF, the Parties
have caused this Agreement to be duly executed as of the date hereof.
|
FOXO Technologies Inc. |
|
|
|
|
By: |
|
|
Name: |
Tyler Danielson |
|
Title: |
Interim Chief Executive Officer |
Company Signature Page to Stock Purchase
Agreement
IN WITNESS WHEREOF, the undersigned
have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
Name of Buyer: ________________________________________________________
Signature of Authorized Signatory of Buyer:
_________________________________
Name of Authorized Signatory: _______________________________________________
Title of Authorized Signatory: ________________________________________________
Email Address of Authorized Signatory: _________________________________________
Address for Notice to Buyer:
Address for Delivery of Shares to Buyer (if not
same as address for notice):
First Tranche Purchase Price: $_________________
First Tranche Purchase Shares: _________________
Second Tranche Purchase Price: $_________________
Second Tranche Purchase Shares: _________________
Buyer Signature Page to Stock Purchase
Agreement
EXHIBIT A
Form of Registration Rights Agreement
See Exhibit 10.2 to this Current Report on Form 8-K
Exhibit 10.2
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS
AGREEMENT (this “Agreement”) is made and entered into as of July [●], 2023, by and among FOXO Technologies Inc.,
a Delaware corporation (the “Company”), and each Holder (as defined below) named on the signature pages attached hereto.
This Agreement is made pursuant to the Stock Purchase Agreement, dated as of the date hereof, by and between the Company and the Holder
(the “Purchase Agreement”).
The Company and the Holders hereby agrees as
follows:
1. Definitions.
Capitalized terms used and
not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.
As used in this Agreement, the following terms shall have the following meanings:
“Advice”
shall have the meaning set forth in Section 6(d).
“Effectiveness
Deadline” means, with respect to the Initial Registration Statement required to be filed hereunder, the 45th calendar
day following Filing Deadline (or, in the event of a substantive review by the Commission, the 90th calendar day following
the Filing Deadline) and with respect to any additional Registration Statements which may be required pursuant to Section 2(c), the 30th
calendar day following the date on which an additional Registration Statement is required to be filed hereunder (or, in the event
of a substantive review by the Commission, the 90th calendar day following the date such additional Registration Statement
is required to be filed hereunder); provided, however, that in the event the Company is notified by the Commission that one or more of
the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Deadline
as to such Registration Statement shall be the fifth (5th) Trading Day following the date on which the Company is so notified
if such date precedes the dates otherwise required above; provided, further, that if such Effectiveness Deadline falls on a day that
is not a Trading Day, then the Effectiveness Deadline shall be the next succeeding Trading Day.
“Effectiveness
Period” shall have the meaning set forth in Section 2(a).
“Filing
Deadline” means, with respect to the Initial Registration Statement required hereunder, the 7th calendar day following
the date of execution of this Agreement, and with respect to any additional Registration Statements which may be required pursuant to
Section 2(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement
related to the Registrable Securities.
“Holder”
or “Holders” means the holder or holders, as the case may be, from time-to-time of Registrable Securities.
“Indemnified
Party” shall have the meaning set forth in Section 5(c).
“Indemnifying
Party” shall have the meaning set forth in Section 5(c).
“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.
“Losses”
shall have the meaning set forth in Section 5(a).
“Plan
of Distribution” shall have the meaning set forth in Section 2(a).
“Proceeding(s)”
means any writ, injunction, decree, order, judgment, lawsuit, claim, action, arbitration, proceeding, investigation, summons, audit or
hearing (in each case, whether civil, criminal, administrative, investigative or informal) commenced, brought, conducted or heard by
or before, or otherwise involving, any governmental authority.
“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.
“Registrable
Securities” means, as of any date of determination, (a) all shares of Common Stock issued pursuant to the Purchase Agreement,
and (b) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event
with respect to the foregoing; provided, however, that the Holder has completed and delivered to the Company a Selling Stockholder Questionnaire
and that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain
the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as: (x) a Registration
Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and
such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (y) such Registrable
Securities have been previously sold in accordance with Rule 144, or (z) such securities become eligible for resale without volume or
manner-of-sale restrictions pursuant to Rule 144 (assuming that such securities and any securities issuable upon exercise, conversion
or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate
of the Company), as reasonably determined by the Company, upon the advice of counsel to the Company.
“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c), including (in each case) the Prospectus, amendments, and supplements to any such registration
statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference
or deemed to be incorporated by reference in any such registration statement.
“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.
“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.
“Selling
Stockholder Questionnaire” means a questionnaire in the form attached as Annex B hereto, or such other form of questionnaire
as may reasonably be adopted by the Company from time to time.
“SEC Guidance”
means (i) any publicly available written or oral guidance of the Commission staff, or any comments, requirements, or requests of the
Commission staff and (ii) the Securities Act.
2. Resale
Registration.
(a) On
or prior to each Filing Deadline, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a
continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-1 (or Form S-3, if available to
register for resale the Registrable Securities, or such other form available to register for resale the Registrable Securities) and shall
contain substantially the “Plan of Distribution” attached hereto as Annex A. Subject to the terms of this Agreement,
the Company shall use its commercially reasonable efforts to cause a Registration Statement filed under this Agreement to be declared
effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness
Deadline, and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities
Act until the earlier of (i) six (6) months after the Initial Registration Statement has been declared effective by the Commission or
(ii) the date that all Registrable Securities covered by such Registration Statement (A) have been sold, thereunder or pursuant to Rule
144, or (B) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company
to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant
to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the “Effectiveness
Period”). The Company shall promptly notify the Holders via e-mail of the effectiveness of a Registration Statement. The Company
shall file a final Prospectus with the Commission as required by Rule 424.
(b) Notwithstanding
the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities
cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement,
the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the
Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered
by the Commission, on Form S-1 or such other form available to register for resale the Registrable Securities as a secondary offering.
(c) Notwithstanding
any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities
permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used
commercially reasonable efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities),
unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered
on such Registration Statement will be reduced first to reduce or eliminate any securities to be included by any Person other than a
Holder. In the event of a cutback hereunder, the Company shall give a Holder at least two (2) Trading Days prior written notice along
with the calculations as to such Holder’s allotment. In the event the Company amends the Initial Registration Statement in accordance
with the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission
or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-1 or
such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration
Statement, as amended.
(d) Each
Holder agrees to furnish to the Company a completed Selling Stockholder Questionnaire within two (2) Business Days following the date
of this Agreement. Each Holder further agrees that it shall not be entitled to be named as a selling security holder in the Registration
Statement or use the Prospectus for offers and resales of Registrable Securities at any time unless such Holder has returned to the Company
a completed and signed Selling Stockholder Questionnaire. If a Holder of Registrable Securities returns a Selling Stockholder Questionnaire
after the deadline specified in this Section 2(d), the Company shall use its commercially reasonable efforts to take such actions as
are required to name such Holder as a selling security holder in the Registration Statement or any pre-effective or post-effective amendment
thereto and to include (to the extent not theretofore included) in the Registration Statement the Registrable Securities identified in
such late Selling Stockholder Questionnaire; provided that the Company shall not be required to file an additional Registration Statement
solely for such shares. Each Holder acknowledges and agrees that the information in the Selling Stockholder Questionnaire will be used
and relied upon by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information
in the Registration Statement.
3. Registration
Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:
(a) Not
less than [one (1) Trading Day][two (2) Trading Days] prior to the filing of each Registration Statement, the Company shall: (i) furnish
to each Holder copies of all such documents proposed to be filed, which documents will be subject to the reasonable review of such Holders,
and (ii) use its commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants
to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable
investigation within the meaning of the Securities Act. Notwithstanding the foregoing, the Company shall not be obligated to provide
the Holders advanced copies of any proposed universal shelf registration statement registering securities in addition to those securities
required to be registered hereunder.
(b) (i)
Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement used in connection
therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for
the Effectiveness Period and prepare and file with the Commission such additional Registration Statement(s) in order to register for
resale under the Securities Act any and all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented,
from time to time, by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended,
to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably practicable to any comments received from the Commission with
respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably practicable to the Holders true, accurate
and complete copies of all correspondence from and to the Commission related to and/or applicable to a Holder in the reasonable opinion
of the Company relating to a Registration Statement (provided that, the Company shall excise its business judgment with regard to any
information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries),
and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the
disposition of all Registrable Securities covered by a Registration Statement during the Effectiveness Period in accordance (subject
to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement
as so amended or in such Prospectus as so supplemented.
(c) Notify
the Holders of Registrable Securities intended to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied
by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible
(and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm
such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective
amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a “review”
of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to
a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or
any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional
information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, and (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration
Statement stale or otherwise ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any material
revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus,
as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; provided,
however, in no event shall any such notice contain any information which would constitute material, non-public information regarding
the Company or any of its Subsidiaries.
(d) Use
its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending
the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of
the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.
(e) Subject
to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by
each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any
amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(c).
(f) Prior
to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with
the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of such
Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States
as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the
Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions
of the Registrable Securities covered by each Registration Statement; provided, that, the Company shall not be required to qualify generally
to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.
(g) If
requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates or direct registration
statements in book entry form representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement,
which certificates shall be free, to the extent permitted by the Purchase Agreement (solely with respect to Holders a party thereto)
and applicable securities laws, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and
registered in such names as any such Holder may reasonably request.
(h) Upon
the occurrence of any event contemplated by Section 3(c), as promptly as reasonably practicable under the circumstances taking into account
the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure
of any such event, prepare a supplement or amendment, including a post-effective amendment to a Registration Statement or a supplement
to any related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required
document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain any untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading at the time made. If the Company notifies the Holders in accordance with
Section 3(c) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders
shall suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus
may be resumed as promptly as is practicable. In addition, if (i) there is material non-public information regarding the Company which
the Company’s Board of Directors (the “Board”) determines not to be in the Company’s best interest to
disclose and which the Company is not otherwise required to disclose, or (ii) there is a significant business opportunity (including,
but not limited to, the acquisition or disposition of assets (other than in the ordinary course of business) or any merger, consolidation,
tender offer or other similar transaction) available to the Company which the Board determines not to be in the Company’s best
interest to disclose, then the Company may (x) postpone or suspend filing of a registration statement for a period not to exceed forty-five
(45) consecutive days or (y) postpone or suspend effectiveness of a registration statement for a period not to exceed forty-five (45)
consecutive days; provided, that the Company may not postpone or suspend effectiveness of a registration statement under this Section
for more than ninety (90) days in the aggregate during any three hundred sixty (360) day period; provided, however, that no such postponement
or suspension shall be permitted for consecutive twenty (20) day periods arising out of the same set of facts, circumstances or transactions.
(i) Comply in all material
respects with all applicable rules and regulations of the Commission.
(j) The
Company shall require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock
beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control
over the shares, pursuant to the Selling Stockholder Questionnaire.
4. Registration
Expenses. All fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by
the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to
in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees
and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the
Commission, (B) with respect to filings required to be made with any Principal Market on which the Common Stock is then listed for trading,
and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without
limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable
Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii)
messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance,
if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with
the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal
expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation,
all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the
fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder.
In no event shall the Company be responsible for any broker or similar commissions of any Holder or any legal fees, or other costs of
the Holders.
5. Indemnification.
(a) Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the
officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as
a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other
Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title)
of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally
equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person,
to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising
out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the
case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such
untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder
expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution
of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement,
such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose)
or (ii) in the case of an occurrence of an event of the type specified in Section 3(c)(iii)-(vi), the use by such Holder of an outdated,
defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated,
defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section
6(d). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection
with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities
by any of the Holders in accordance with Section 6(h).
(b) Indemnification
by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents
and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law,
from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of
a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information
so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii)
to the extent, but only to the extent, that such information relates to such Holder’s information provided in the Selling Stockholder
Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by
such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose),
such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than
the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and
the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by
such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.
(c) Conduct
of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder
(an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the
“Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including
the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection
with defense thereof; provided, that, the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party
of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by
a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially
and adversely prejudiced the Indemnifying Party.
An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees
and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed
in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding
and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such
Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified
Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified
Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects
to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense
thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party).
The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent
shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party,
effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.
Subject to the
terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent
incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall
be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party; provided,
that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to
such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not
subject to appeal or further review) not to be entitled to indemnification hereunder.
(d) Contribution.
If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party
harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such
proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions,
statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such
Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made
by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party
as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’
or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified
for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.
The parties hereto
agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or
by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding
paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount
of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any
damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
The indemnity and
contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties.
6. Miscellaneous.
(a) Remedies.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the
Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including
recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder
agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach,
it shall not assert or shall waive the defense that a remedy at law would be adequate.
(b) No
Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except as contemplated by Section 6(e) herein, and
except as set forth in Schedule I attached hereto, neither the Company nor any of its security holders (other than the Holders
in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities.
Except in connection with the items described in Schedule I attached hereto, the Company shall not file any other registration
statements until a Registration Statement has been filed with the Commission covering all of the Registrable Securities, provided that
this Section 6(b), (i) shall not prohibit the Company from filing amendments to registration statements filed prior to the date of this
Agreement and (ii) shall not prohibit the Company from filing a shelf registration statement on Form S-3 for a primary offering by the
Company, provided that the Company makes no offering of securities pursuant to such shelf registration statement prior to the effective
date of the Registration Statement required hereunder that includes all of the Registrable Securities; provided, however, that upon the
filing of a Registration Statement covering all of the Registrable Securities, the Company shall be permitted to file any other registration
statements in connection with a primary offering regardless of whether a Registration Statement covering all of the Registrable Securities
has been declared effective by the Commission; provided, further, that once all Registrable Securities are registered pursuant to a Registration
Statement that is declared effective by the Commission, the Company shall be permitted to file any other registration statements.
(c) Compliance.
Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to
it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to a Registration Statement.
(d) Discontinued
Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event of the kind described in Section 3(c), such Holder will forthwith discontinue disposition of such Registrable
Securities under a Registration Statement until it is advised in writing (the “Advice”) by the Company that the use
of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its commercially reasonable
efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.
(e) Piggy-Back
Registrations. If, at any time during the Effectiveness Period, there is not an effective Registration Statement covering all of
the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating
to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form
S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely
in connection with any acquisition of any entity or business or equity securities issuable in connection with the Company’s stock
option or other employee benefit plans, then the Company shall deliver to each Holder a written notice of such determination and, if
within ten (10) days after the date of the delivery of such notice, any such Holder shall so request in writing, the Company shall include
in such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided, however,
that the Company shall not be required to register any Registrable Securities pursuant to this Section 6(e) that are eligible for resale
pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Commission pursuant
to the Securities Act or that are the subject of a then effective Registration Statement. In connection with any offering involving an
underwriting of shares of the Company’s capital stock, the Company shall not be required to include any of the Registrable Securities
in such underwriting unless the Holder accepts the terms of the underwriting as agreed upon between the Company and its underwriters,
and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering
by the Company. If the total number of securities, requested by stockholders to be included in such offering exceeds the number of securities
to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable
Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering.
If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering,
then the Registrable Securities that are included in such offering shall be allocated among the Holders of Registrable Securities in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each Holder requesting registration.
(f) Amendments
and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified, or supplemented,
and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by
the Company and the Holders of at least a majority of the then outstanding Registrable Securities. If a Registration Statement does not
register all the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number
of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the
right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing,
a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder
or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders
of all the Registrable Securities to which such waiver or consent relates. No consideration shall be offered or paid to any Person to
amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all
the parties to this Agreement.
(g) Notices.
All notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the
Purchase Agreement.
(h) Successors
and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the
parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder
without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their
respective rights hereunder to any Person to whom such Holder assigns or transfers any Registrable Securities, provided that such transferee
agrees in writing to be bound, with respect to the transferred Registrable Securities, by the provisions of this Agreement and any other
Transaction Document that applies to the Holders.
(i) No
Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company
or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would
have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts in any material respect with
the provisions hereof. Neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration
rights with respect to any of its securities to any Person that have not been satisfied in full, except in connection with the items
described in Schedule I attached hereto.
(j) Execution
and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page was an original thereof.
(k) Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in
accordance with the provisions of the Purchase Agreement.
(l) Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.
(m) Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants, and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.
(n) Headings.
The headings in this Agreement are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof.
(o) Independent
Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations
of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder
hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder
pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other
kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect
to such obligations or the transactions contemplated by this Agreement or any other matters. Each Holder shall be entitled to protect
and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any
other Holder to be joined as an additional party in any proceeding for such purpose. It is expressly understood and agreed that each
provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively
and not between and among Holders.
********************
(Signature Pages Follow)
IN WITNESS WHEREOF, the
parties have executed this Registration Rights Agreement as of the date first written above.
|
FOXO Technologies INC. |
|
|
|
|
|
By: |
|
|
|
Name: |
Tyler Danielson |
|
|
Title: |
Interim Chief Executive Officer |
[SIGNATURE PAGE OF HOLDERS FOLLOWS]
[SIGNATURE
PAGE OF HOLDERS TO RRA]
Name of Holder:
Signature of Authorized Signatory of Holder:
__________________________
Name of Authorized Signatory:
Title of Authorized Signatory:
SCHEDULE I
Reference is made
to the terms of:
| ● | the Warrant Agreement, dated December 10, 2020, between the
Company and Continental Stock Transfer & Trust Company, as Warrant Agent; |
| ● | the Registration Rights Agreement, dated December 10, 2020,
by and among the Company and certain security holders; |
| ● | the Company’s Offer to Exchange Warrants to Acquire
Shares of Class A Common Stock and Consent Solicitation, commenced on April 27, 2023; |
| ● | the Company’s Offer to Amend 15% Senior Promissory
Notes and Consent Solicitation, commenced on April 27, 2023; |
| ● | the general release agreement, dated as of June 16, 2023,
between the Company and Baboon Partners, LLC, a former holder of 10% Original Issue Discount Convertible Debentures issued in 2022 by
FOXO Technologies Operating Company (“2022 Bridge Debentures”); |
| ● | the general release agreement, dated as of June 20, 2023,
between the Company and Inpixon, a former holder of 2022 Bridge Debentures; |
| ● | any additional general release agreements that the Company
may enter into with any former holders of 2022 Bridge Debentures that have not executed a general release agreement as of the date of
this Agreement; and |
| ● | each registration rights agreement that the Company has entered
into or may enter into with an investor in connection with such investor’s purchase of shares in a private placement of the Company’s
Class A common stock, $0.0001 par value, pursuant to a stock purchase agreement with terms substantially similar to the terms of the
Purchase Agreement. |
Annex A
Plan of Distribution
Each Selling Stockholder
(the “Selling Stockholders”) of the securities and any of their pledgees, assignees and successors-in-interest may,
from time to time, sell any or all of their securities covered hereby on the Principal Market or any other stock exchange, market or
trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling
Stockholder may use any one or more of the following methods when selling securities:
| ● | ordinary brokerage
transactions and transactions in which the broker-dealer solicits purchasers; |
| ● | block trades in which
the broker-dealer will attempt to sell the securities as agent but may position and resell
a portion of the block as principal to facilitate the transaction; |
| ● | purchases by a broker-dealer
as principal and resale by the broker-dealer for its account; |
| ● | an exchange distribution
in accordance with the rules of the applicable exchange; |
| ● | privately negotiated
transactions; |
| ● | settlement of short
sales; |
| ● | in transactions through
broker-dealers that agree with the Selling Stockholders to sell a specified number of such
securities at a stipulated price per security; |
| ● | through the writing
or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; |
| ● | a combination of any
such methods of sale; or |
| ● | any other method permitted
pursuant to applicable law. |
The Selling Stockholders
may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the “Securities
Act”), if available, rather than under this prospectus.
Broker-dealers engaged by
the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of
a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2440.
In connection with the sale
of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling
Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The Selling Stockholders
and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the
Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.
The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Stockholders against certain losses, claims, damages, and liabilities, including liabilities under the Securities Act.
We agreed to keep this prospectus
effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and
without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance
with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities
have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition,
in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification requirement is available and is complied with.
Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in
market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to
the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common
stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and
have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).
Annex B
FOXO
Technologies INC.
Selling Stockholder Notice and Questionnaire
The undersigned beneficial
owner of Class A Common Stock (the “Registrable Securities”) of FOXO Technologies Inc., a Delaware corporation (the
“Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission
(the “Commission”) a registration statement (the “Registration Statement”) for the registration
and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities,
in accordance with the terms of the Registration Rights Agreement (the “Registration Rights Agreement”) to which this
document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth
below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.
In order to sell or otherwise
dispose of any Registrable Securities pursuant to the Registration Statement, a holder of Registrable Securities generally will be required
to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented, the “Prospectus”),
deliver the Prospectus to Holders of Registrable Securities (including pursuant to Rule 172 under the Securities Act) and be bound by
the provisions of the Registration Rights Agreement (including certain indemnification provisions, as described below). Holders must
complete and deliver this Notice and Questionnaire to be named as selling stockholders in the Prospectus. Holders of Registrable Securities
who do not complete, execute, and return this Notice and Questionnaire within ten (10) Business Days following the date of the Agreement
(1) will not be named as selling stockholders in the Resale Registration Statement or the Prospectus and (2) may not use the Prospectus
for resales of Registrable Securities.
Certain legal consequences
arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial
owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or
not being named as a selling stockholder in the Registration Statement and the related prospectus.
NOTICE
The undersigned beneficial
owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable Securities owned
by it in the Registration Statement. The undersigned hereby provides the following information to the Company and represents and warrants
that such information is accurate:
QUESTIONNAIRE
| (a) | Full Legal Name of Selling Stockholder |
| (b) | Full Legal Name of Registered Holder (if
not the same as (a) above) through which Registrable Securities are held: |
| (c) | Full Legal Name of Natural Control Person
(which means a natural person who directly or indirectly alone or with others has power to
vote or dispose of the securities covered by this Questionnaire): |
2. Address for
Notices to Selling Stockholder:
|
|
|
|
|
|
Telephone: |
|
|
Fax: |
|
|
Contact Person: |
|
3. Broker-Dealer
Status:
| (a) | Are you a broker-dealer? |
| (b) | If “yes” to Section 3(a),
did you receive your Registrable Securities as compensation for investment banking services
to the Company? |
| Note: | If “no” to Section 3(b), the Commission’s
staff has indicated that you should be identified as an underwriter in the Registration Statement. |
| (c) | Are you an affiliate of a broker-dealer? |
| (d) | If you are an affiliate of a broker-dealer,
do you certify that you purchased the Registrable Securities in the ordinary course of business,
and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable
Securities? |
| Note: | If “no” to Section 3(d), the Commission’s
staff has indicated that you should be identified as an underwriter in the Registration Statement. |
4. Beneficial Ownership
of Securities of the Company Owned by the Selling Stockholder.
Except as set forth below in this
Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable
pursuant to the Purchase Agreement.
| (a) | Type and Amount of other securities beneficially
owned by the Selling Stockholder: |
| (b) | Number of shares of Common Stock to be
registered pursuant to this Notice for resale: |
5. Relationships
with the Company:
Except as set forth below, neither
the undersigned nor any of its affiliates, officers, directors, or principal equity holders (owners of 5% of more of the equity securities
of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors
or affiliates) during the past three years.
State any exceptions
here:
The undersigned agrees to
promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof
at any time while the Registration Statement remains effective.
By signing below, the undersigned
consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information
in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.
IN WITNESS WHEREOF the undersigned,
by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized
agent.
EXHIBIT B
Form of Buyer Questionnaire
ACCREDITED INVESTOR QUESTIONNAIRE
FOXO TECHNOLOGIES INC.
This Questionnaire is being distributed to certain
entities in connection with the proposed issuance of Class A Common Stock to you by FOXO Technologies Inc., a Delaware corporation (the
“Company”). The purpose of this Questionnaire is to assure the Company that all such offers and purchases will
meet the standards imposed by the Securities Act of 1933, as amended (the “Act”), and applicable state securities
laws.
All answers will be kept confidential. However,
by signing this Questionnaire, the undersigned agrees that this information may be provided by the Company to its legal and financial
advisors, and the Company and such advisors may rely on the information set forth in this Questionnaire for purposes of complying with
all applicable securities laws and may present this Questionnaire to such parties as it reasonably deems appropriate if called upon to
establish its compliance with such securities laws. The undersigned represents that the information contained herein is complete and
accurate and will notify the Company of any material change in any of such information prior to the undersigned’s investment in
the Company.
For
Entity Investors
Accredited Investor Certification. The
undersigned makes one of the following representations regarding its net worth and certain related matters and has checked the
applicable representation:
| [__] | The undersigned is a trust with total assets in excess of
$5,000,000 whose purchase is directed by a person with such knowledge and experience in financial and business matters that such person
is capable of evaluating the merits and risks of the prospective investment. |
| [__] | The undersigned is a bank, an investment adviser registered
pursuant to Section 203 of the Advisers Act or registered pursuant to the laws of a state, any investment adviser relying on the exemption
from registering with the SEC under Section 203(l) or (m) of the Advisers Act, an insurance company, an investment company registered
under the United States Investment Company Act of 1940, as amended, a broker or dealer registered pursuant to Section 15 of the United
States Securities Exchange Act of 1934, as amended, a business development company, a Small Business Investment Company licensed by the
United States Small Business Administration, a Rural Business Investment Company as defined in Section 384A of the Consolidated Farm
and Rural Development Act, as amended, a plan with total assets in excess of $5,000,000 established and maintained by a state for the
benefit of its employees, or a private business development company as defined in Section 202(a)(22) of the Advisers Act. |
| [__] | The undersigned is an employee benefit plan and either
all investment decisions are made by a bank, savings and loan association, insurance company, or registered investment advisor, or
the undersigned has total assets in excess of $5,000,000 or, if such plan is a self-directed plan, investment decisions are
made solely by persons who are accredited investors. |
| [__] | The undersigned is a corporation, limited liability company,
partnership, business trust, not formed for the purpose of acquiring the Securities, or an organization described in Section 501(c)(3)
of the Internal Revenue Code of 1986, as amended (the “Code”), in each case with total assets in excess of
$5,000,000. |
| [__] | The undersigned is an entity in which all of the equity
owners (in the case of a revocable living trust, its grantor(s)) qualify under any of the above subparagraphs, or, if an individual,
each such individual has a net worth,1
either individually or upon a joint basis with such individual’s spouse or spousal equivalent2,,
as applicable, in excess of $1,000,000 (within the meaning of such terms as used in the definition of “accredited investor”
contained in Rule 501 under the Act), or has had an individual income3
in excess of $200,000 for each of the two most recent years, or a joint income with such individual’s spouse or spousal
equivalent, as applicable, in excess of $300,000 in each of those years, and has a reasonable expectation of reaching the same income
level in the current year. |
| [__] | The
undersigned is an entity, of a type not listed in any of the paragraphs above, which was not formed for the specific purpose of acquiring
the securities offered, owning investments in excess of $5,000,000. |
| [__] | The
undersigned is a “family office,” as defined in rule 202(a)(11)(G)-1 under the Advisers Act, (i) with assets under
management in excess of $5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose
prospective investment is directed by a person who has such knowledge and experience in financial and business matters that such family
office is capable of evaluating the merits and risks of the prospective investment. |
| [__] | The
undersigned is a “family client,” as defined in rule 202(a)(11)(G)-1 under the Advisers Act, of a family office meeting the
requirements in the above paragraph and whose prospective investment is directed by such family office pursuant to clause (iii) of the
above paragraph. |
| [__] | The undersigned cannot make any of the representations set
forth above. |
For
Individual Investors
Accredited Investor Certification. The
undersigned makes one of the following representations regarding its income, net worth, status as a “family client” of a
“family office,” and/or certain professional certifications or designations and certain related matters and has checked
the applicable representation:
| [__] | The undersigned’s income3 during each of
the last two years exceeded $200,000 or, if the undersigned is married or has a spousal equivalent2, the joint income of the
undersigned and the undersigned’s spouse or spousal equivalent, as applicable, during each of the last two years exceed $300,000,
and the undersigned reasonably expects the undersigned’s income, from all sources during this year, will exceed $200,000 or, if
the undersigned is married or has a spousal equivalent, the joint income of undersigned and the undersigned’s spouse or spousal
equivalent, as applicable, from all sources during this year will exceed $300,000. |
| [__] | The
undersigned’s net worth,1 including the net worth of the undersigned’s
spouse or spousal equivalent, as applicable, is in excess of $1,000,000 (excluding the value of the undersigned’s
primary residence). |
| [__] | The undersigned is a holder in good standing of one or more
of the following certifications or designations administered by the Financial Industry Regulatory Authority, Inc. (FINRA): the Licensed
General Securities Representative (Series 7), Licensed Investment Adviser Representative (Series 65), or Licensed Private Securities
Offerings Representative (Series 82). |
| [__] | The
undersigned is a “family client,” as defined in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940, as
amended (the “Advisers Act”), of a family office as
defined in rule 202(a)(11)(G)-1 under the Advisers Act, (i) with assets under management in excess of $5,000,000, (ii) that is
not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment is directed by a person
who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and
risks of the prospective investment, and whose prospective investment
is directed by such family office pursuant to clause (iii) of this sentence. |
| [__] | The undersigned cannot make any of the representations set
forth above. |
| 1 | For purposes of this Questionnaire, “net worth”
means the excess of total assets, excluding your primary residence, at fair market value over total liabilities, including your mortgage
or any other liability secured by your primary residence only if and to the extent that it exceeds the value of your primary residence.
Net worth should include the value of any other shares of stock or options held by you and your spouse or spousal equivalent and any
personal property owned by you or your spouse or spousal equivalent (e.g. furniture, jewelry, other valuables, etc.). For the
purposes of calculating joint net worth: joint net worth can be the aggregate net worth of you and your spouse or spousal equivalent;
assets need not be held jointly to be included in the calculation. |
2 | For purposes of this Questionnaire, “spousal
equivalent” means a cohabitant occupying a relationship generally equivalent to that of a spouse. |
3 | For purposes of this Questionnaire, “income”
means adjusted gross income, as reported for federal income tax purposes, increased by the following amounts: (a) the amount of
any tax exempt interest income received, (b) the amount of losses claimed as a limited partner in a limited partnership, (c) any
deduction claimed for depletion, (d) amounts contributed to an IRA or Keogh retirement plan, (e) alimony paid, and (f) any
amounts by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions
of Section 1202 of the Code. |
[Signature
Page Follows]
In
Witness Whereof, the undersigned has executed this Accredited Investor Questionnaire as of the date written below.
|
|
|
Name of Investor |
|
|
|
|
|
(Signature) |
|
|
|
|
|
Name of Signing Party (Please Print) |
|
|
|
|
|
Title of Signing Party (Please Print) |
|
|
|
|
|
Address |
|
|
|
|
|
Email |
|
|
|
|
|
Date Signed |
25
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024